

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Thursday 04 February 2021

Time: 8:30am to 9:30am

Location:

9(2)(k)

Chair:

Dr Ian Town

Members:

Dr David Murdoch, Prof Peter McIntyre, Dr Nikki Turner, Dr Nikki Moreland, Assoc Prof James Ussher, Dr Pippa Scott, Dr Tony Walls, Dr Sean Hanna, Dr Elizabeth Wilson

Ministry of Health Attendees:

Dr Caroline McElnay, Daniel Bernal, s 9(2)(a), Fiona Callaghan

Guests:

s 9(2)(a)

Apologies:

Assoc Prof Sue Crengle, Dr Matire Harwood, s 9(2)(a), Dr Helen Petousis-Harris, Dr John Taylor, Prof Ian Frazer

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccine TAG Minutes 02 Feb 2021
2.0	COVID-19 IIAG Update		Information	Dr Nikki Turner Dr Helen Petousis-Harris	
3.0	Pfizer Vaccine Science Overview			Pippa Scott	 Pfizer Vaccine Science Overview_021  Pfizer - data update_02Feb2021b.c  Taskforce Candidate Science Overview - Pf

4.0	Pfizer Data Sheet			Chair	 ds-clean.pdf  cmi-nz-clean-6-doses.pdf
5.0	Questions on the Pfizer Vaccine		Discussion	Chair	 Vaccine Technical Advisory Group - Que
6.0	COVID-19 Immunisation Target		Discussion	Chair	 DRAFT Health Report Indicative Targets for
7.0	Any Other Business			All	Verbal
8.0	Agenda items for next meeting			Chair	

RELEASED UNDER THE OFFICAL INFORMATION ACT 1982

Open Actions:

Action #	Agenda item	Actions	Action Owner	Updates	Status
03	Questions on the Pfizer Vaccine	Group to consider questions under items 8 and 9 (in the memo to the Vaccine TAG) for further discussion on Thursday.	All	02/02 - Action raised	Open
04	Questions on the Pfizer Vaccine	Prof McIntyre to work with Dr Scott on drafting responses to these questions.	Prof Peter McIntyre Dr Pippa Scott	02/02 - Action raised	Open

Closed Actions:

Action #	Agenda item	Actions	Action Owner	Updates	Status
01	Role of the COVID-19 IIAG	Standing agenda item to be added: Update from IIAG.	Chair	02/02 - Action raised 03/02 – Agenda updated	Closed
02	Pfizer Vaccine Science Overview	A3 overview to be sent to the group, including new members.	Dr Pippa Scott	02/02 - Action raised 03/02 – Document distributed	Closed

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 02 March 2021

Time: 12:30pm to 2:00pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, John Taylor, Matire Harwood, Nikki Moreland, Nikki Turner, Peter McIntyre, Pippa Scott, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Caroline McElroy, Daniel Bernal, Juliet Rumball-Smith, Fiona Callaghan, s 9(2)(a)

Guests: s 9(2)(a)

Apologies:

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccine TAG Minutes 19 Fe
2.0	Science Updates			Pippa Scott	 APA_vaccines_data update_01March2
3.0	Research in Children			Pippa Scott	 Childhood_Covid_acc_trials_010321.c
4.0	Vaccines in Pregnancy			Chair	 Vaccination again COVID in Pregnan
5.0	Vaccine Sitrep			Chair	

6.0	Vaccine Deployment in an Outbreak			s 9(2)(a) [REDACTED]	 DRAFT Use of COVID-19 vaccines
7.0	Vaccine Sequencing			Chair	
8.0	30-Minute Observation Time Post Vaccine			Juliet Rumball-Smith	 Reconsideration of observation time C
9.0	Concomitant Delivery of Vaccines			Nikki Turner	See email
10.0	Proactive Position Statement on Vaccinating Children			Elizabeth Wilson Peter McIntyre Tony Walls	Verbal
11.0	Next Steps/Decisions Pending			All	Verbal
12.0	Any Other Business			All	Verbal
13.0	Agenda items for next meeting			Chair	

Open Actions:

#	Agenda item	Action	Action Owner	Updates	Status
04	Questions on the Pfizer Vaccine	Consultation with Edwin Reynolds re immune checkpoint inhibitors	Nikki Turner	04/02 - Action raised	Open
05	Patient information sheet and data sheet	Ask Medsafe to include more specific information re anaphylaxis in data sheet	Chair	04/02 - Action raised	Open
06	Overview of Immunisation rollout	Include information on respiratory vaccine side-reactions in the post-vaccination information sheet	STA Team	19/02 - Action raised	Open
08	Vaccines for Children	Work towards a proactive position statement on vaccinating children	Peter McIntyre Tony Walls Elizabeth Wilson	19/02 - Action raised	Open
11	Baseline Survey of Adverse Events	Provide a brief written report on progress of the work	Helen Petousis-Harris	19/02 - Action raised	Open

Closed Actions Since Last Meeting:

#	Agenda item	Actions	Action Owner	Updates	Status
07	Vaccines for Children	Provide a written summary of the current state of trials planned in children	Pippa Scott	19/02 - Action raised 01/03 - Document included in the agenda for 02/03 meeting	Closed
09	Using Pfizer/BioNTech Vaccine as Post-exposure Prophylaxis in a COVID-19 Outbreak	Amend the memo to include suggestions by the Chair and circulate to CV TAG	s 9(2)(a)	19/02 - Action raised 01/03 - Updated memo included in the agenda for 02/03 meeting	Closed
10	Pillar 7 Activities 5.a - Adverse Event Committee	Circulate the TOR and membership for the COVID-19 Independent Safety Monitoring Board	Tim Hanlon	19/02 - Action raised 24/02 – Documents circulated	Closed

RELEASED UNDER THE OFFICIAL INFORMATION ACT 1982

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 09 March 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, John Taylor, Matire Harwood, Nikki Moreland, Nikki Turner, Peter McIntyre, Pippa Scott, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Caroline McElnay, Daniel Bernal, Juliet Rumball-Smith, Fiona Callaghan, s 9(2)(a) Shayma Faircloth

Guests: s 9(2)(a)

Apologies:

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccine TAG Minutes 02 M
2.0	Science Updates <i>Note paper for reference but there are no substantial changes since last week</i>		Information	Pippa Scott	 APA_vaccines_data update_08March2
3.0	Research in Children <i>Note paper for reference but there are no substantial changes since last week</i>		Information	Pippa Scott	 Childhood_Covid_acc_trials_080321.c
4.0	Vaccine Guidance to Cancer Clinicians			Dan Bernal	 DRAFT Vaccine information for cand
5.0	Baseline Survey of Adverse Events			Helen Petousis-Harris	 SAFE update Ma 8.pdf

6.0	Pfizer Dosing Interval			Chair	
7.0	Vaccine Rollout			Chair	 Daily COVID-19 Vaccination Repo
8.0	Next Steps/Decisions Pending			All	Verbal
9.0	Any Other Business			All	Verbal
10.0	Agenda items for next meeting			Chair	

Open Actions:

#	Agenda item	Action	Action Owner	Updates
08	Vaccines for Children	Work towards a proactive position statement on vaccinating children	Peter McIntyre Tony Walls Elizabeth Wilson	19/02 - Action raised 02/03 - Tony Walls provided an overview of the recommendations, final document will be circulated for consideration.
15	Concomitant Delivery of Vaccines	Discuss this topic at the COVID Expert Advisory meeting in Australia	Ian Frazer	02/03 - Action raised
16	Concomitant Delivery of Vaccines	Talk to Fran Priddy regarding research on this topic	Chair	02/03 - Action raised

Closed Actions Since Last Meeting:

#	Agenda item	Actions	Action Owner	Updates
04	Questions on the Pfizer Vaccine	Consultation with Edwin Reynolds re immune checkpoint inhibitors	Nikki Turner	04/02 - Action raised 02/03 - Nikki Turner noted that Edwin is a key expert for adult high-risk groups and recommended that Edwin be considered to join the CV TAG. The Chair accepted the recommendation. Nikki will send the contact details to the Chair.

05	Patient information sheet and data sheet	Ask Medsafe to include more specific information re anaphylaxis in data sheet	Chair	04/02 - Action raised 02/03 - STA Team to cross-check that the Medsafe data sheet lines with material from the Ministry and IMAC.
06	Overview of Immunisation rollout	Include information on respiratory vaccine side-reactions in the post-vaccination information sheet	STA Team	19/02 - Action raised 02/03 - Handled directly by clinical leads in conjunction with the immunisation rollout team.
07	Vaccines for Children	Provide a written summary of the current state of trials planned in children	Pippa Scott	19/02 - Action raised 01/03 - Document included in the agenda for 02/03 meeting
09	Using Pfizer/BioNTech Vaccine as Post-exposure Prophylaxis in a COVID-19 Outbreak	Amend the memo to include suggestions by the Chair and circulate to CV TAG	s 9(2)(a)	19/02 - Action raised 01/03 - Updated memo included in the agenda for 02/03 meeting
10	Pillar 7 Activities 5.a - Adverse Event Committee	Circulate the TOR and membership for the COVID-19 Independent Safety Monitoring Board	Tim Hanlon	19/02 - Action raised 24/02 – Documents circulated
11	Baseline Survey of Adverse Events	Provide a brief written report on progress of the work	Helen Petousis-Harris	19/02 - Action raised 02/03 - Helen Petousis-Harris to provide a preliminary report at the next CV TAG meeting. 08/03 – Included in the agenda for 09/03 meeting
12	Vaccines in Pregnancy	Send information document to Minister Verrall's office	Chair	02/03 - Action raised 03/03 – Action completed
13	Vaccine Sitrep	Send report to CV TAG members	Chair	02/03 - Action raised 08/03 – Included in the agenda for 09/03 meeting
14	Vaccine Sitrep	Check with Intel team whether there will be a publicly facing register	STA Team	02/03 - Action raised 03/03 – Action completed
17	30-Minute Observation Time Post Vaccine	Send revised documentation to CV TAG members	Juliet Rumball-Smith	02/03 - Action raised 03/03 – Action completed

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 23 March 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] s 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Edwin Reynolds, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, John Taylor, Matire Harwood, Nikki Moreland, Nikki Turner, Peter McIntyre, Pippa Scott, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Caroline McElroy, Daniel Bernal, Juliet Rumball-Smith, Fiona Callaghan, s 9(2)(a) Shayma Faircloth

Guests: s 9(2)(a) 2)(a)

Apologies:

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccine TAG Minutes 09 M
2.0	Science Updates		Information	Pippa Scott	 APA_vaccines_data_pdate_22March2021  Pfizer Vaccine Science Overview_2
3.0	Research in Children		Information	Pippa Scott	 Childhood_Covid_Vcc_trials_220321.doc
4.0	Revised VAANZ Cohort Study; Flu Co-administration			s 9(2)(a)	 COVID-19 Vaccine Immunogenicity Sy

5.0	Health Advice on Symptoms 48 hours Post Vaccination – Discrepancy for Border Workers			Dan Bernal	 2021 03 23 CVTAC cover memo testin  RFA Post-vaccine AEs.docx
8.0	Next Steps/Decisions Pending			All	Verbal
9.0	Any Other Business			All	Verbal
10.0	Agenda items for next meeting			Chair	

Open Actions:

#	Agenda item	Action	Action Owner	Updates
08	Vaccines for Children	Work towards a proactive position statement on vaccinating children	Peter McIntyre Tony Walls Elizabeth Wilson	19/02 - Action raised 02/03 - Tony Walls provided an overview of the recommendations, final document will be circulated for consideration. 09/03 - Tony will circulate the documentation when ready.
18	Vaccine Rollout	Contact Medsafe about progress of Janssen approval	STA Team	09/03 - Action raised
19	Vaccine Guidance to Cancer Clinicians	Talk to the Immunisation team regarding removal of cautionary advice on ICIs for the flu vaccine	Caroline McElnay	09/03 - Action raised
20	Any Other Business	Contact Medsafe about stability of Pfizer vaccine	STA Team	09/03 - Action raised

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 13 April 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] s 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Edwin Reynolds, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, John Taylor, Matire Harwood, Nikki Moreland, Nikki Turner, Peter McIntyre, Pippa Scott, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Caroline McElnay, Daniel Bernal, Juliet Rumball-Smith, Fiona Callaghan, s 9(2)(a) Shayma Faircloth

Guests: s 9(2)(a)

Apologies:

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccine TAG Minutes 23 Ma
2.0	Science Updates		Information	Pippa Scott	 Pfizer Vaccine Science Overview_  APA_vaccines_data update_10April202
3.0	Research in Children		Information	Pippa Scott	 Childhood_Covid_V acc_trials_07Apr21 T
4.0	Vaccine Rollout		Update	Chair	

5.0	<p>Overlap Influenza Campaign</p> <p>A recent Health Report on this subject that was send to Ministers on 19 March 2021.</p> <p>The Minister indicated his report for Option 2 in the paper.</p>			Chair	 Signed HR 20210649.pdf  Appendix 1 HR20210649.pdf  Appendix 2 HR20210649.pdf
6.0	CV ISMB Memo Update		Discussion	Chair	 CV-ISMB meeting_3 March update.docx  Guideline Protocol for Hypersensitivity  ASCIA_HP_Position_tatement_COVID-19  Anaphylaxis vs Stres WHO.docx  Anaphylaxis Tabula Checklist for Key Cas
7.0	48h Testing Advice		Information	Chair	 DRAFT Testing guidance for COV
8.0	Interchangeability of COVID-19 Vaccines		Information	Chair	 Memo_COVID-19 Vaccine Technical
9.0	Janssen Decision to Use		Information	Chair	 J&J vaccine Scienc overview_12April20
10.0	AZ and Risk of Blood Clots		Discussion	Chair	 20210412_AstraZe eca_vaccine_blood
11.0	Next Steps/Decisions Pending			All	Verbal

12.0	Any Other Business			All	Verbal
13.0	Agenda items for next meeting			Chair	

Open Actions:

#	Agenda item	Action	Action Owner	Updates
19	Vaccine Guidance to Cancer Clinicians	Talk to the Immunisation team regarding removal of cautionary advice on ICIs for the flu vaccine	Caroline McElnay	09/03 - Action raised
21	Health Advice on Symptoms 48 hours Post Vaccination – Discrepancy for Border Workers	Draft a proposed guidance document and email to CV TAG for review	Juliet-Rumball Smith s 9(2)(a)	23/03 - Action raised

RELEASED UNDER THE OFFICAL INFORMATION ACT 1982

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 27 April 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k) [REDACTED]

Chair: Ian Town

Members: David Murdoch, Edwin Reynolds, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, John Taylor, Matire Harwood, Nikki Moreland, Nikki Turner, Peter McIntyre, Pippa Scott, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Caroline McElnay, Daniel Bernal, Juliet Rumball-Smith, Fiona Callaghan, s 9(2)(a) [REDACTED], Shayma Faircloth

Guests:

Apologies:

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccine TAG Minutes 13 Apr
2.0	Science Updates		Information	Pippa Scott	 Pfizer Vaccine Science Overview_1  APA_vaccines_data_pdate_19April2021_  COVID-19 Vaccine tables 3 -23rd April_  Science overview o Janssen COVID-19 v

3.0	Research in Children		Information	Pippa Scott	 Childhood_Covid_V cc_trials_18Apr21_F
4.0	Vaccine Rollout		Update	Chair	
5.0	Baseline Survey of Adverse Events		Update	Helen Petousis-Harris	To follow
6.0	Serological Survey Protocol ** Confidential and not for further distribution **		Information	s 9(2)(a)	 Research Protocol_Queenstow  Research Protocol_v.5.8_4 SEP
				Nikki Moreland	 PrePrint Charting Elimination in the Pa  20210413 PrePrint Appendix Charting E
7.0	Next Steps/Decisions Pending			All	Verbal
8.0	Any Other Business			All	Verbal
13.0	Agenda items for next meeting			Chair	

Open Actions:

#	Agenda item	Action	Action Owner	Updates
19	Vaccine Guidance to Cancer Clinicians	Talk to the Immunisation team regarding removal of cautionary advice on ICIs for the flu vaccine	Caroline McElnay	09/03 - Action raised
22	Vaccine Rollout	Escalate the issues related to the CIR system with Joanne Gibbs (Director of CVIP)	Juliet Rumball-Smith Nikki Turner	13/04 - Action raised
23	CV ISMB Memo Update	Meet with CV ISMB to establish a clear line of communication and escalation	Chair	13/04 - Action raised
24	Interchangeability of COVID-19 Vaccines	Notify the CVIP that vaccine doses of arrivals should be	Juliet Rumball-Smith	13/04 - Action raised

		appropriately recorded on the CIR		
25	Janssen Decision to Use	Enquire about acquiring the Moderna vaccine	STA Team	13/04 - Action raised

RELEASED UNDER THE OFFICAL INFORMATION ACT 1982

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 11 May 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Edwin Reynolds, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, John Taylor, Matire Harwood, Nikki Moreland, Nikki Turner, Peter McIntyre, Pippa Scott, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Caroline McElnay, Daniel Bernal, Juliet Rumball-Smith, s 9(2)(a), [REDACTED], Shayma Faircloth; s 9(2)(a)

Guests: s 9(2)(a)

Apologies: Fiona Callaghan

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccine TAG Minutes 27 Apr
2.0	Science Updates		Information	Pippa Scott	 Pfizer Vaccine Science Overview_8  APA_vaccines_data_update_8thMay2021a  Science overview o Janssen COVID-19 v  COVID-19 Vaccine tables 4 - 6 May 202

3.0	Research in Children		Information	Pippa Scott	 Childhood_Covid_V cc_trials_8th May_dr
4.0	Vaccine Rollout		Update	Chair	
5.0	Update on Adverse Event Reporting (CIR system)		Discussion	s 9(2)(a) [REDACTED]	 CVIP Post Event workstream update.
6.0	Ring Vaccination		Discussion	Dan Bernal s 9(2)(a) [REDACTED]	 Memo to CV TAG - Ring Vaccination 7M
7.0	Next Steps/Decisions Pending			All	Verbal
8.0	Any Other Business			All	Verbal
13.0	Agenda items for next meeting			Chair	

Open Actions:

#	Agenda item	Action	Action Owner	Updates
22	Vaccine Rollout	Escalate the issues related to the CIR system with Joanne Gibbs (Director of CVIP)	Juliet Rumball-Smith Nikki Turner	13/04 - Action raised 27/04 - Chair noted that these issues are being worked through. A report is being prepared and will be sent to CV TAG shortly.
23	CV ISMB Memo Update	Meet with CV ISMB to establish a clear line of communication and escalation	Chair	13/04 - Action raised 27/04 - Chair noted that there are still some articulation issues between the CV ISMB, the CV TAG, and the steering group, which are being worked on.
26	Science Updates	Circulate updated guidance from Cancer Control Agency to CV TAG	Chair	27/04 - Action raised
27	Vaccine Rollout	Follow up with the CIR team to ensure that the administrative timing is not mistaken as a clinical recommendation	Juliet-Rumball Smith	27/04 - Action raised

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 25 May 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Edwin Reynolds, Elizabeth Wilson, Helen Petousis-Harris, , James Ussher, John Taylor, Matire Harwood, Nikki Moreland, Nikki Turner, Peter McIntyre, Pippa Scott, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Caroline McElroy, Daniel Bernal, Fiona Callaghan, Juliet Rumball-Smith, s 9(2)(a) Shayma Faircloth

Guests: s 9(2)(a)

Apologies: Ian Frazer, Sean Hanna

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccine TAG Minutes 11 M
2.0	Science Updates <i>These are final, peer-reviewed updates</i>		Information	Pippa Scott	 COVID-19 Vaccine tables 5 (20 May 2021)  Pfizer Vaccine Science Overview_2  Janssen Vaccine Science Overview_2
3.0	Research in Children <i>These are final, peer-reviewed updates</i>		Information	Pippa Scott	 Childhood_Covid_Vcc_trials_23rd May_
4.0	Vaccine Rollout		Update	Chair	

5.0	Research Project on BMI and Immunogenicity		Discussion	Chair s 9(2)(a) [REDACTED]	 The effect of bod mass index and ar
6.0	Pfizer Decision to use Tier 3		Discussion	s 9(2)(a) [REDACTED]	 Memo CVTAG Pfize D2U Tier 3_CSA_DB
7.0	Pregnancy Advice		Discussion	Edwin Reynolds	 COVID and COVID vaccines in pregnanc  Strawman Statement.docx
8.0	Long-term effects of Pfizer vaccine		Discussion	Dan Bernal	 Draft statement c Long-term effects
9.0	Next Steps/Decisions Pending			All	Verbal
10.0	Any Other Business			All	Verbal
11.0	Agenda items for next meeting			Chair	

RELEASED UNDER THE OFFICIAL INFORMATION ACT 1982

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 08 June 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Edwin Reynolds, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Matire Harwood, Nikki Moreland, Nikki Turner, Peter McIntyre, Pippa Scott, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Caroline McElnay, Daniel Bernal, Fiona Callaghan, Juliet Rumball-Smith, s 9(2)(a), Shayma Faircloth

Guests: s 9(2)(a)

Apologies:

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccine TAG Minutes 25 Ma
2.0	Science Updates These are final, peer-reviewed updates		Information	Pippa Scott	 COVID-19 Vaccine tables 6 (2 June 2021)  Science overview of Janssen COVID-19 v  Pfizer Vaccine Science Overview_2n  Novavax Vaccine Science Overview_2 AZ Science Overview to follow

3.0	Research in Children These are final, peer-reviewed updates		Information	Pippa Scott	 COVID Vaccine trial in children_2Jun202
4.0	Vaccine Rollout		Update	Chair	
5.0	Research Prioritisation Framework		Discussion	s 9(2)(a)	 Prioritisation Framework Memo.d
6.0	Decision to Use Pfizer for 12 -15 years		Discussion	s 9(2)(a)	 Decision to Use Pfizer for 12-15 years men
7.0	Upcoming decisions on Janssen and AZ		Discussion	s 9(2)(a)	Verbal
8.0	Next Steps/Decisions Pending			All	Verbal
9.0	Any Other Business			All	Verbal
10.0	Agenda Items for Next Meeting			Chair	

RELEASED UNDER THE OFFICIAL INFORMATION ACT 1982

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 22 June 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] s 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Edwin Reynolds, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Matire Harwood, Nikki Moreland, Nikki Turner, Peter McIntyre, Pippa Scott, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Caroline McElnay, Daniel Bernal, Fiona Callaghan, Juliet Rumball-Smith, s 9(2)(a), Shayma Faircloth, Niki Stefanogiannis

Guests: s 9(2)(a)

Apologies:

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccine TAG Minutes 08 Jun
2.0	Science Updates These are final, peer-reviewed updates		Information	STA	 COVID-19 Vaccine tables 7 (17 June 20)  Pfizer Vaccine Science Overview_1  AstraZeneca Vaccin Science Overview_1  Janssen Vaccine Science Overview17

					 Novavax Vaccine Science Overview_1
3.0	Research in Children These are final, peer-reviewed updates		Information	STA	 COVID Vaccine trial in children_17June2
4.0	Vaccine Rollout		Update	Chair	
5.0	Decision to Use Jansen ** Data sheets are sensitive documents and not yet released publicly – shared in-confidence, not for further distribution.		Discussion	s 9(2)(a)	 CV-TAG Janssen Vaccine_CSA (003).  DRAFT Janssen DATA SHEET 17062
6.0	Decision to Use Pfizer for 12 -15 years ** Data sheets are sensitive documents and not yet released publicly – shared in-confidence, not for further distribution.		Discussion	s 9(2)(a)	 Decision to Use Pfizer for 12-15 year  DRAFT Pfizer DATA SHEET 170621.pdf
7.0	Mixed Vaccines for the Border Order		Discussion	s 9(2)(a) Dan Bernal	 Memo to CV TAG - Other COVID-19 vac
8.0	Next Steps/Decisions Pending			All	Verbal
9.0	Any Other Business			All	Verbal
10.0	Agenda Items for Next Meeting			Chair	

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 29 June 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Edwin Reynolds, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Nikki Turner, Peter McIntyre, Pippa Scott, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Caroline McElnay, Daniel Bernal, Fiona Callaghan, Juliet Rumball-Smith, s 9(2)(a) [REDACTED] Shayma Faircloth, Niki Stefanogiannis, s 9(2)(a) [REDACTED]

Guests: s 9(2)(a) [REDACTED]

Apologies:

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccine TAG Minutes 22 Jun
2.0	Myocarditis after Pfizer Vaccination		Discussion	Chair	 Myocarditis - ACIP meeting 23rd June 2  3rd report to the Ministry of Health B
3.0	COVID-19 Vaccination in the Frail Elderly		Discussion	s 9(2)(a) [REDACTED] Juliet Rumball-Smith	 COVID-19 Vaccination in the Ex
4.0	Next Steps/Decisions Pending			All	Verbal
5.0	Any Other Business			All	Verbal

6.0	Agenda Items for Next Meeting			Chair	
-----	-------------------------------	--	--	-------	--

RELEASED UNDER THE OFFICAL INFORMATION ACT 1982

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 06 July 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Edwin Reynolds, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Nikki Turner, Peter McIntyre, Pippa Scott, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Caroline McElroy, Daniel Bernal, Fiona Callaghan, Juliet Rumball-Smith, s 9(2)(a), Shayma Faircloth, Niki Stefanogiannis

Guests: s 9(2)(a)

Apologies:

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccine TAG Minutes 29 Jun
2.0	Science Updates These are final, peer-reviewed updates		Information	STA	 COVID-19 Vaccine Tables 8 (1st July 20)  Pfizer Vaccine Science Overview_1  AstraZeneca Vaccin Science Overview_1  Janssen_Vaccine_Science_Overview_01Ju

					 Novavax Vaccine Science Overview_1
3.0	Research in Children These are final, peer-reviewed updates		Information	STA	 COVID Vaccine Trial in Children_1July_FI
4.0	Vaccine Rollout		Update	Chair	Verbal
5.0	Janssen - Decision to Use		Update	Chair	Verbal
6.0	Myocarditis after Pfizer Vaccination		Discussion	Chair	 245 Myocarditis Update for CV TAG (
7.0	VAANZ Research Update		Update	David Murdoch	Verbal
8.0	Next Steps/Decisions Pending			All	Verbal
9.0	Any Other Business			All	Verbal
10.0	Agenda Items for Next Meeting			Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
29	Myocarditis after Pfizer Vaccination	Draft message for Ministry of Health Comms on the risks of myocarditis.	Secretariat	29/06 - Action raised
30	Myocarditis after Pfizer Vaccination	Convene a subgroup of CV TAG to advise on the risk of myocarditis.	Secretariat	29/06 - Action raised
31	Myocarditis after Pfizer Vaccination	Request data from CVIP on numbers <30 in each group.	Secretariat	29/06 – Action raised
32	Myocarditis after Pfizer Vaccination	Request behavioural insights information on vaccine hesitancy among <30	Secretariat	29/06 – Action raised

Closed Actions Since Last Meeting:

#	Agenda item	Actions	Action Owner	Updates
---	-------------	---------	--------------	---------

28	Vaccine rollout	Follow up with CVIP data team on ethnic reporting	Secretariat	22/06 - Action raised 30/06 - Email update provided to Sue Crengle
----	-----------------	---	-------------	---

RELEASED UNDER THE OFFICAL INFORMATION ACT 1982

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 13 July 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Nikki Turner, Peter McIntyre, Pippa Scott, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Caroline McElnay, Daniel Bernal, Edwin Reynolds, Fiona Callaghan, Juliet Rumball-Smith, s 9(2)(a), Shayma Faircloth, Niki Stefanogiannis, s 9(2)(a)

Guests: s 9(2)(a)

Apologies:

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccine TAG Minutes 06 July
2.0	Vaccine Rollout		Update	Chair	Verbal
3.0	Children Priority Groups		Discussion	Chair	 Draft recommendations for  Memo CV TAG Recommendations for
4.0	Myocarditis Recommendations		Information	Chair	 Memo CV TAG Myocarditis following
5.0	Next Steps/Decisions Pending			All	Verbal

6.0	Any Other Business			All	Verbal
7.0	Agenda Items for Next Meeting			Chair	Verbal

Open Actions:

None

Closed Actions Since Last Meeting:

#	Agenda item	Actions	Action Owner	Updates
28	Vaccine rollout	Follow up with CVIP data team on ethnic reporting	Secretariat	22/06 - Action raised 30/06 - Email update provided to Sue Crengle
29	Myocarditis after Pfizer Vaccination	Draft message for Ministry of Health Comms on the risks of myocarditis.	Secretariat	29/06 - Action raised 30/06 - Message signed off and sent to Comms
30	Myocarditis after Pfizer Vaccination	Convene a subgroup of CV TAG to advise on the risk of myocarditis.	Secretariat	29/06 - Action raised 30/06 - Subgroup convened and provided advice
31	Myocarditis after Pfizer Vaccination	Request data from CVIP on numbers <30 in each group.	Secretariat	29/06 – Action raised 01/07 - Data received and incorporated into request for advice on myocarditis
32	Myocarditis after Pfizer Vaccination	Request behavioural insights information on vaccine hesitancy among <30	Secretariat	29/06 – Action raised 01/07 - Data received and incorporated into request for advice on myocarditis

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 20 July 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, Nikki Moreland, Nikki Turner, Peter McIntyre, Pippa Scott, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Caroline McElroy, Daniel Bernal, Edwin Reynolds, Fiona Callaghan, Juliet Rumball-Smith, s 9(2)(a) [REDACTED] Niki Stefanogiannis, s 9(2)(a) [REDACTED]

Guests: s 9(2)(a) [REDACTED]

Apologies: Andi Shirtcliffe, James Ussher, Shayma Faircloth

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccine TAG Minutes 13 Ju
2.0	Science Updates These are final, peer-reviewed updates		Information	STA	 COVID-19 Vaccine Tables 9 (15 July 2021)  Pfizer Vaccine Science Overview_1  AstraZeneca Vaccine Science Overview_1  Janssen_Vaccine_Science_Overview_15Ju

					 Novavax Vaccine Science Overview_1
3.0	Research in Children These are final, peer-reviewed updates		Information	STA	 COVID Vaccine Trial in Children_15July20
4.0	Vaccine Rollout		Update	Chair	Verbal
5.0	Myocarditis Recommendations Update		Update	Chair	 Memo CV TAG Myocarditis followin
6.0	Children Priority Groups		Discussion	Chair	 Draft recommendations fo  Memo CV TAG Recommendations fo
7.0	Next Steps/Decisions Pending			All	Verbal
8.0	Any Other Business			All	Verbal
9.0	Agenda Items for Next Meeting			Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
33	Myocarditis after Pfizer Vaccination	Update message for Ministry of Health Comms on the risks of myocarditis.	Secretariat	13/07 - Action raised
34	Myocarditis after Pfizer Vaccination	Compile information on cardiac-related events associated with other vaccines in New Zealand's portfolio.	Secretariat	13/07 - Action raised

Closed Actions Since Last Meeting:

#	Agenda item	Actions	Action Owner	Updates
---	-------------	---------	--------------	---------

29	Myocarditis after Pfizer Vaccination	Draft message for Ministry of Health Comms on the risks of myocarditis.	Secretariat	29/06 - Action raised 30/06 - Message signed off and sent to Comms
30	Myocarditis after Pfizer Vaccination	Convene a subgroup of CV TAG to advise on the risk of myocarditis.	Secretariat	29/06 - Action raised 30/06 - Subgroup convened and provided advice
31	Myocarditis after Pfizer Vaccination	Request data from CVIP on numbers <30 in each group.	Secretariat	29/06 – Action raised 01/07 - Data received and incorporated into request for advice on myocarditis
32	Myocarditis after Pfizer Vaccination	Request behavioural insights information on vaccine hesitancy among <30	Secretariat	29/06 – Action raised 01/07 - Data received and incorporated into request for advice on myocarditis

RELEASED UNDER THE OFFICIAL INFORMATION ACT

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 27 July 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k) [REDACTED]

Chair: Ian Town

Members: Elizabeth Wilson, James Ussher, Nikki Moreland, Nikki Turner, Peter McIntyre, Pippa Scott, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Caroline McElnay, Daniel Bernal, Edwin Reynolds, Fiona Callaghan, Juliet Rumball-Smith, Niki Stefanogiannis, s 9(2)(a) [REDACTED], Shayma Faircloth

Guests:

Apologies: David Murdoch, Helen Petousis-Harris, Ian Frazer

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccine TAG Minutes 20 July
2.0	Myocarditis Recommendations Update		Update	Chair	 Memo CV TAG Myocarditis followin
3.0	Decision to Use Pfizer 12-15 Year olds		Discussion	Chair	 Memo CV TAG recommendations fo
4.0	Children Priority Groups		Discussion	Chair	 Memo CV TAG Children Priority Gro
5.0	Next Steps/Decisions Pending			All	Verbal
6.0	Any Other Business			All	Verbal
7.0	Agenda Items for Next Meeting			Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
33	Myocarditis after Pfizer Vaccination	Update message for Ministry of Health Comms on the risks of myocarditis.	Secretariat	13/07 - Action raised 16/07 - Message updated and awaiting sign-off
34	Myocarditis after Pfizer Vaccination	Compile information on cardiac-related events associated with other vaccines in New Zealand's portfolio.	Secretariat	13/07 - Action raised
35	Science Updates	Compile and monitor updates on reduced Pfizer doses among children	Secretariat	20/07 - Action raised
36	Myocarditis after Pfizer Vaccination	Collate feedback on Medsafe's Myocarditis alert communication	Secretariat	20/07 - Action raised
37	Children priority groups	Update recommendations on children priority groups	Secretariat	20/07 - Action raised
38	Decision to Use Janssen	Add people with severe disabilities who find vaccination difficult as a priority group for Janssen	Secretariat	20/07 - Action raised

RELEASED UNDER THE OFFICIAL INFORMATION ACT 1982

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 03 August 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Elizabeth Wilson, James Ussher, Helen Petousis-Harris, Ian Frazer, Nikki Moreland, Nikki Turner, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Caroline McElroy, Daniel Bernal, Edwin Reynolds, Fiona Callaghan, Juliet Rumball-Smith, Niki Stefanogiannis, s 9(2)(a), Shayma Faircloth, s 9(2)(a)

Guests: s 9(2)(a)

Apologies:

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccine TAG Minutes 27 July
2.0	Science Updates These are final, peer-reviewed updates		Information	STA	 COVID-19 Vaccine Tables 10 (28 July)_  Pfizer Vaccine Science Overview 28  Janssen_Vaccine_Science_Overview_28Ju AstraZeneca and Novavax to follow

3.0	Research in Children These are final, peer-reviewed updates		Information	STA	 COVID Vaccine Trial in Children_28July2
5.0	Myocarditis Recommendations Update		Update	Chair	Verbal
6.0	Children Priority Groups		Discussion	Chair	 Memo CV TAG Children Priority Gro
7.0	Dosing Interval for Pfizer		Discussion	Chair	 274 STA_Request_for_Ad
8.0	Future Vaccine Portfolio		Discussion	Chair	 252 Future Vaccine Needs in NZ_29July
9.0	MMR/Influenza Co-administration		Discussion	Chair	 258 MMR coadministration w
10.0	Next Steps/Decisions Pending			All	Verbal
11.0	Any Other Business			All	Verbal
12.0	Agenda Items for Next Meeting			Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
33	Myocarditis after Pfizer Vaccination	Update message for Ministry of Health Comms on the risks of myocarditis.	Secretariat	13/07 - Action raised 28/07 - CVIP Comms progressing this this week.
34	Myocarditis after Pfizer Vaccination	Compile information on cardiac-related events associated with other vaccines in New Zealand's portfolio.	Secretariat	13/07 - Action raised 27/07 - Drafted. Awaiting peer review
39	Myocarditis after Pfizer Vaccination	Share draft messaging and timelines with CV TAG when available	Secretariat	27/07 - Action raised

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 17 August 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] s 9(2)(k)

Chair: Ian Town

Members: Elizabeth Wilson, James Ussher, Helen Petousis-Harris, Ian Frazer, Nikki Moreland, Nikki Turner, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Daniel Bernal, Edwin Reynolds, Fiona Callaghan, Juliet Rumball-Smith, Niki Stefanogiannis, s 9(2)(a), Shayma Faircloth, s 9(2)(a)

Guests: s 9(2)(as 9(2)(a))

Apologies: David Murdoch, Caroline McElnay

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccin TAG Minutes 3 Aug
2.0	Science Updates These are final, peer-reviewed updates		Information	STA	 COVID-19 Vaccin Tables 11 (13 Aug)  Pfizer Vaccine Science Overview_  AstraZeneca Vaccin Science Overview_1  Janssen_Vaccine_S nce_Overview_13A

					 Novavax Vaccine Science Overview_
3.0	Research in Children These are final, peer-reviewed updates		Information	STA	 COVID Vaccine Trial in Children_13Aug
4.0	Vaccine rollout update		Information	Chair	Verbal
5.0	Dosing Interval for Pfizer		Update	Chair	Verbal
6.0	Myocarditis after Pfizer vaccination		Update	Chair	Verbal
7.0	Decision to use for 12-15-year olds		Update	Chair	Verbal
8.0	MMR/Influenza Co-administration		Discussion	Chair	 Memo to CV-TAG Vaccine coadminist
9.0	Other COVID-19 vaccines that New Zealand could recognise for border workers		Discussion	s 9(2)(a)	 Memo - CV-TAG Other COVID-19 va
10.0	Next Steps/Decisions Pending			All	Verbal
11.0	Any Other Business			All	Verbal
12.0	Agenda Items for Next Meeting			Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
34	Myocarditis after Pfizer Vaccination	Compile information on cardiac-related events associated with other vaccines in New Zealand's portfolio.	Secretariat	13/07 - Action raised 27/07 - Drafted. Awaiting peer review
39	Myocarditis after Pfizer Vaccination	Share draft messaging and timelines with CV TAG when available	Secretariat	27/07 - Action raised
40	Decision to Use Pfizer 12 to 15-year-olds and Children Priority Groups	Update memo and RfA and circulate	Chair and Secretariat	03/08 - Action raised
41	Dosing interval	RfA shared with Director-General	Secretariat	03/08 - Action raised

42	Future Vaccine Portfolio	Update RfA and share with Policy	Secretariat	03/08 - Action raised
43	MMR/Influenza Coadministration	Update RfA with clinical trial data	Secretariat	03/08 - Action raised
44	MMR/Influenza Coadministration	Convene working group to draft recommendations	Secretariat	03/08 - Action raised

RELEASED UNDER THE OFFICAL INFORMATION ACT 1982

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 31 August 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: Elizabeth Wilson, James Ussher, Helen Petousis-Harris, Ian Frazer, Nikki Moreland, Nikki Turner, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe s 9(2)(a) [REDACTED], Caroline McElroy, Daniel Bernal, David Murdoch, Edwin Reynolds, Fiona Callaghan, Juliet Rumball-Smith, Niki Stefanogiannis, s 9(2)(a) [REDACTED] Shayma Faircloth

Guests: s 9(2)(a) [REDACTED]

Apologies:

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccin TAG Minutes 17 A
2.0	Vaccine rollout update		Information	Chair	Verbal
3.0	MMR/ Influenza Coadministration		Update	Chair	Verbal
4.0	Myocarditis		Update	Chair	Verbal
5.0	Third dose		Discussion	Chair/STA	 CSU 46_XX Augu 2021_for CV TAG.d
6.0	Pfizer vaccine dosing error		Discussion	Juliet Rumball-Smith	 Memo for CVTA feedback - Protoc

7.0	Other COVID-19 vaccines that New Zealand could recognise for border workers		Discussion	STA	 Memo - CV-TAG Other COVID-19 va
8.0	Next Steps/Decisions Pending			All	Verbal
9.0	Any Other Business			All	Verbal
10.0	Agenda Items for Next Meeting			Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
34	Myocarditis after Pfizer Vaccination	Compile information on cardiac-related events associated with other vaccines in New Zealand's portfolio.	Secretariat	13/07 - Action raised 27/07 - Drafted. Awaiting peer review
47	Other COVID-19 Vaccines that New Zealand Could Recognise	Compile evidence on protection offered by other vaccines and partial vaccination	STA	17/08 - Action raised

RELEASED UNDER THE OFFICIAL INFORMATION ACT 1982

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 07 September 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Nikki Turner, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, s 9(2)(a), Caroline McElnay, Daniel Bernal, Edwin Reynolds, Fiona Callaghan, Juliet Rumball-Smith, Niki Stefanogiannis, s 9(2)(a), [REDACTED], Shayma Faircloth

Guests: s 9(2)(a) 2(a)

Apologies:

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccin TAG Minutes 31 Au
2.0	Influenza Programme 2022		Discussion	s 9(2)(a) [REDACTED]	 CVTAG Memo - Influenza 2022.do  ESR-Priority Disea Threats To Consid  ESR- Respiratory Syncytial Virus (RS
3.0	Guidance for Cancer Patients		Noting	Chair	 vaccine-informati -for-cancer-clinici

4.0	Third dose for immunocompromised		Discussion	STA	 Memo - CV TAG Additional dose in
5.0	Vaccines Recognised for Border Workers		Update	Chair	Verbal
6.0	Vaccines Recognised for Returnees		Discussion	s 9(2)(a) [REDACTED]	 Memo - CV-TAG - COVID-19 vaccines
7.0	Next Steps/Decisions Pending			All	Verbal
8.0	Any Other Business			All	Verbal
9.0	Agenda Items for Next Meeting			Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
34	Myocarditis after Pfizer Vaccination	Compile information on cardiac-related events associated with other vaccines in New Zealand's portfolio.	Secretariat	13/07 - Action raised 27/07 - Drafted. Awaiting peer review
48	MMR/Influenza Coadministration	Follow-up on announcement.	Chair	31/08 – Action raised
49	Pfizer dosing error	Compile further evidence on the link between dosing intervals and reactogenicity.	Science and Technical Advisory	31/08 – Action raised

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 14 September 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Nikki Turner, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, s 9(2)(a), Caroline McElnay, s 9(2)(a), Daniel Bernal, Edwin Reynolds, Fiona Callaghan, Juliet Rumball-Smith, Niki Stefanogiannis, s 9(2)(a), Shayma Faircloth

Guests: s 9(2)(a)

Apologies:

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccine TAG Minutes 07
2.0	Science Updates These are final, peer-reviewed updates		Information	STA	 COVID-19 Vaccine Tables 12 (10 Sep)  Pfizer Vaccine Science Overview  AstraZeneca Vaccine Science Overview  Janssen_Vaccine Science Overview_1

					 Novavax Vacc Science Overvie
3.0	Research in Children These are final, peer-reviewed updates		Information	STA	 COVID Vaccine in Children_105
4.0	Vaccine Rollout		Update	Chair	Verbal
5.0	Third Dose for Immunocompromised		Discussion	STA	 Memo - CV TA Additional dose
6.0	Vaccines to be Recognised for Arrivals		Discussion	s 9(2)(a)	 Memo - CV-TA COVID-19 vacci
7.0	Next Steps/Decisions Pending			All	Verbal
8.0	Any Other Business			All	Verbal
9.0	Agenda Items for Next Meeting			Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
49	Pfizer dosing error	Compile further evidence on the link between dosing intervals and reactogenicity.	Science and Technical Advisory	31/08 – Action raised
51	Third Dose for Immunocompromised	Convene subgroup to redraft recommendations	Science and Technical Advisory	07/09 – Action raised
52	Vaccines Recognised for Returnees	Draft CV TAG recommendations and bring back to group	Science and Technical Advisory	07/09 – Action raised
53	Vaccine rollout	Request CVIP update on final stages of rollout plan	Secretariat	07/09 – Action raised
54	Vaccine rollout	Request CVIP data on coverage by ethnicity	Secretariat	07/09 – Action raised

55	Extension dose protocol for missed vaccination events	Share finalised memo with Immunisation Advisory Centre	Secretariat	07/09 – Action raised
----	---	--	-------------	-----------------------

RELEASED UNDER THE OFFICAL INFORMATION ACT 1982

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 21 September 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Nikki Turner, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, s 9(2)(a), Caroline McElnay, s 9(2)(a), Daniel Bernal, Edwin Reynolds, Fiona Callaghan, Juliet Rumball-Smith, Niki Stefanogiannis, s 9(2)(a), Shayma Faircloth

Guests: s 9(2)(a) (2)(a)

Apologies:

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccine TAG Minutes 14
2.0	Vaccine Rollout/Delta Outbreak		Update	Chair	Verbal
3.0	Third Dose for Immunocompromised		Update	STA	 Memo - CV TAG Additional dose
4.0	Vaccines to be Recognised for Arrivals		Discussion	STA	 Memo - CV-TAG COVID-19 vaccine
5.0	Third booster doses		Discussion	Chair	 JCVI statement regarding a COVID-19 vaccine

6.0	Decision to use for 12-15 year olds (review)		Discussion	Chair	Verbal
7.0	Next Steps/Decisions Pending			All	Verbal
8.0	Any Other Business			All	Verbal
9.0	Agenda Items for Next Meeting			Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
49	Pfizer dosing error	Compile further evidence on the link between dosing intervals and reactogenicity.	Science and Technical Advisory	31/08 – Action raised
52	Vaccines Recognised for Returnees	Draft CV TAG recommendations and bring back to group	Science and Technical Advisory	07/09 – Action raised
56	Third dose for immunocompromised	Finalise recommendations and share with CVIP	Science and Technical Advisory	14/09 – Action raised

RELEASED UNDER THE OFFICIAL INFORMATION ACT 1982

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 05 October 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Nikki Turner, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, s 9(2)(a), Caroline McElnay, s 9(2)(a), Daniel Bernal, Edwin Reynolds, Erin Smith, Fiona Callaghan, Juliet Rumball-Smith, Niki Stefanogiannis, s 9(2)(a)

Guests: s 9(2)(a) (2)(a)

Apologies:

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vacc TAG Minutes 21
2.0	Vaccine Rollout		Update	Chair	Verbal
3.0	Vaccines recognised for MIQ entry and RSE workers		Update	Chair	Verbal
4.0	Supporting evidence for Health Care Worker vaccination order		Discussion	Chair	 DRAFT Healthc workers VOExte
5.0	VAANZ vaccine candidates development update and Research Project		Discussion	James Ussher	 VAANZ 2.0 Presentation to C
6.0	BMI needle length study update		Update	s 9(2)(a)	Verbal

7.0	Science Updates These are final, peer-reviewed updates		Information	STA	 COVID-19 Vaccines Tables 13 (24 Sep)  Pfizer Vaccines Science Overview
8.0	Next Steps/Decisions Pending			All	Verbal
9.0	Any Other Business			All	Verbal
10.0	Agenda Items for Next Meeting			Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
49	Pfizer dosing error	Compile further evidence on the link between dosing intervals and reactogenicity.	Science and Technical Advisory	31/08 – Action raised
56	Third dose for immunocompromised	Finalise recommendations and share with CVIP	Science and Technical Advisory	14/09 – Action raised
57	Third dose for immunocompromised	Share finalised recommendations with IMAC	Secretariat	21/09 – Action raised
58	Vaccines recognised for arrivals	Share lists of vaccines approved with their efficacies to inform discussion	Science and Technical Advisory	21/09 – Action raised
59	Vaccines recognised for arrivals	Request data on positivity rates from MIQ testing requirements	Science and Technical Advisory	21/09 – Action raised
60	Third booster doses	Compile evidence on need for booster doses	Science and Technical Advisory	21/09 – Action raised
61	Decision to use 12-15-year-olds	Reshare statement on the benefit of longer dosing intervals	Secretariat	21/09 – Action raised
62	Any other business	Discuss Pfizer dosing interval with Reti's office	Secretariat	21/09 – Action raised

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 19 October 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Nikki Turner, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, s 9(2)(a), Caroline McElroy s 9(2)(a), Daniel Bernal, Edwin Reynolds, Erin Smith, Fiona Callaghan, Juliet Rumball-Smith, Niki Stefanogiannis, s 9(2)(a)

Guests: s 9(2)(a) (2)(a)

Apologies:

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccination Technical Advisory Group Minutes 05
2.0	Vaccine rollout and outbreak		Update	Chair	Verbal
3.0	Supporting evidence for Healthcare Worker vaccination order		Noting	Chair s 9(2)(a)	Verbal
4.0	Decision to use AstraZeneca		Discussion	s 9(2)(a)	 Memo for CVT Advice - Decision  AstraZeneca Vaccine Science Overview
5.0	Myocarditis update		Discussion	s 9(2)(a)	 334 Update on Myocarditis follow-up

6.0	Decision to use 5-11 year olds		Discussion	Pippa Scott	Verbal
7.0	Next Steps/Decisions Pending			All	Verbal
8.0	Any Other Business			All	Verbal
9.0	Agenda Items for Next Meeting			Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
49	Pfizer dosing error	Compile further evidence on the link between dosing intervals and reactogenicity.	Science and Technical Advisory	31/08 – Action raised
60	Third booster doses	Compile evidence on need for booster doses	Science and Technical Advisory	21/09 – Action raised

Closed Actions Since Last Meeting:

#	Agenda item	Actions	Action Owner	Updates
59	Vaccines recognised for arrivals	Request data on positivity rates from MIQ testing requirements	Science and Technical Advisory	21/09 – Action raised 08/10 - Action closed
63	Vaccines recognised for MIQ entry and RSE workers	Share finalised memos with CV TAG	Secretariat	5/10 – Action raised 08/10 - Action closed

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 02 November 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] s 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Nikki Turner, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: s 9(2)(a), Caroline McElnay, s 9(2)(a), Daniel Bernal, Edwin Reynolds, Erin Smith, Fiona Callaghan, Juliet Rumball-Smith, Niki Stefanogiannis, s 9(2)(a)

Guests: s 9(2)(a)

Apologies: Andi Shirtcliffe

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vac TAG Minutes 19
2.0	Vaccine rollout and outbreak		Update	Chair	Verbal
3.0	Decision to Use AstraZeneca vaccine		Update	Chair	 Memo CV TA recommendatio
4.0	Medical exemptions		Update	Chair Fiona Callaghan	 Medical Exemp CVTAG_202111
5.0	Booster doses		Discussion	Chair s 9(2)(a)	 Memo - CV-TA Booster vaccinat

6.0	'Fully vaccinated' definition		Discussion	s 9(2)(a)	 Memo CV TA Definition of full
7.0	Immunocompromised populations and ATAGI's update guidance		Discussion	Chair	 Memo - CV TA Additional dose  atagi-recommend ns-on-the-use-of-
7.1	Research Studies -VAANZ further funding request		Discussion	David Murdoch Erin Smith	 CV_TAG memo_VAANZ_  VAANZ MO CV-TAG proposa
7.2	-Myocarditis research		Discussion	s 9(2)(a)	 Investigatin Long-Term Effect
7.3	-Research extension: Establishing a foundation for monitoring the safety of COVID-19 vaccines using primary care data.		Discussion	s 9(2)(a) Helen Petousis-Harris	 Memo CV-TA Establishing a fo  Proposal_Monit _Safety_COVID_
8.0	Medsafe provisional approval of the Pfizer vaccine extended Here is a link to the press release: https://www.health.govt.nz/news-media/news-items/medsafe-renews-covid-19-vaccine-provisional-approval		Noting	Chair	 Medsafe extend the provisional a
9.0	Medsafe Safety Report 33		Information		 Safety report #3 16 Oct -PH-TT-V
10.0	Next Steps/Decisions Pending		-	All	Verbal
11.0	Any Other Business		-	All	Verbal
12.0	Agenda Items for Next Meeting		-	Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
49	Pfizer dosing error	Compile further evidence on the link between dosing intervals and reactogenicity.	Science and Technical Advisory	31/08 – Action raised
60	Booster doses	Compile evidence on need for booster doses	Science and Technical Advisory	21/09 – Action raised
64	Supporting Evidence for Healthcare Worker Vaccination Order	Finalise evidence brief and share with CVIP and CV TAG	Science and Technical Advisory	19/10 – Action raised
65	Decision to Use AstraZeneca	Draft recommendations for a Decision to Use memo shared with CV TAG	Science and Technical Advisory	19/10 – Action raised
66	Myocarditis	Convene subgroup to update clinical guidance for primary care	Science and Technical Advisory	19/10 – Action raised
67	Decision to Use 5–11-Year-Olds	Convene subgroup to compile evidence and discuss equity considerations	Science and Technical Advisory	19/10 – Action raised
68	Decision to Use 5–11-Year-Olds	Review Pfizer's application for 12-to-15-year olds for evidence on dosages.	Medsafe	19/10 – Action raised
69	Booster doses	Draft recommendations shared with CV TAG	Science and Technical Advisory	19/10 – Action raised
70	Booster doses	Draft recommendations shared with CV TAG	Science and Technical Advisory	19/10 – Action raised

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 09 November 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Nikki Turner, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: s 9(2)(a), Caroline McElnay, s 9(2)(a), Daniel Bernal, Edwin Reynolds, Erin Smith, Fiona Callaghan, Juliet Rumball-Smith, Niki Stefanogiannis, s 9(2)(a)

Guests: s 9(2)(a)

Apologies: Andi Shirtcliffe

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vac TAG Minutes 02
2.0	Science Updates <i>These are final, peer-reviewed updates</i>		Discussion	Chair	 COVID-19 Vac Tables_5 Novem  Pfizer Vaccin Science Overvie  Novavax Vacc Science Overvie
3.0	Research in Children <i>These are final, peer-reviewed updates</i>		Discussion	Chair	 COVID Vaccine in Children_5 Nd

4.0	Booster doses		Update and sign-off	Chair s 9(2)(a)	 Memo - CV-TA Booster vaccinat
5.0	Provisional approval for Comirnaty vaccine booster dose		Information	Medsafe	 Provisional app for Comirnaty b
6.0	Vaccination in 5-11 year olds		Discussion	Chair s 9(2)(a)	Verbal
7.0	Immunocompromised populations and updated advice		Discussion	Chair s 9(2)(a)	 Memo - CV TA Immunocompro
8.0	Medical Exemptions Memo		Noting	Chair	 Memo - CV TA Medical Exempt
9.0	Definition of fully vaccinated within New Zealand memo		Noting	Chair	 Memo CV TA Definition of full
10.0	Next Steps/Decisions Pending		-	All	Verbal
11.0	Any Other Business		-	All	Verbal
12.0	Agenda Items for Next Meeting		-	Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
49	Pfizer dosing error	Compile further evidence on the link between dosing intervals and reactogenicity.	Science and Technical Advisory	31/08 – Action raised
64	Supporting Evidence for Healthcare Worker Vaccination Order	Finalise evidence brief and share with CVIP and CV TAG	Science and Technical Advisory	19/10 – Action raised
68	Decision to Use 5–11-Year-Olds	Review Pfizer's application for 12-to-15-year olds for evidence on dosages.	Medsafe	19/10 – Action raised
73	Immunocompromised populations and ATAGI's update guidance	Revise memo with CV TAG's feedback and share with CVIP	Science and Technical Advisory	02/11 – Action raised

Closed Actions Since Last Meeting:

#	Agenda item	Actions	Action Owner	Updates
60	Booster doses	Compile evidence on need for booster doses	Science and Technical Advisory	21/09 – Action raised 01/11 – Action closed
65	Decision to Use AstraZeneca	Draft recommendations for a Decision to Use memo shared with CV TAG	Science and Technical Advisory	19/10 – Action raised 29/10 – Action closed
69	Booster doses	Draft recommendations shared with CV TAG	Science and Technical Advisory	19/10 – Action raised 01/11 – Action closed
66	Myocarditis	Convene subgroup to update clinical guidance for primary care	Science and Technical Advisory	19/10 – Action raised 08/11 – Action closed
67	Decision to Use 5–11-Year-Olds	Convene subgroup to compile evidence and discuss equity considerations	Science and Technical Advisory	19/10 – Action raised 03/11 – Action closed
70	Medical exemptions	Revise memo with CV TAG's feedback and share with CVIP	Science and Technical Advisory	02/11 – Action raised 03/11 – Action closed
71	Booster doses	Revise memo with CV TAG's feedback	Science and Technical Advisory	02/11 – Action raised 03/11 – Action closed
72	'Fully vaccinated' definition	Revise memo with CV TAG's feedback	Science and Technical Advisory	02/11 – Action raised 03/11 – Action closed

RELEASED UNDER THE OFFICIAL INFORMATION ACT

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 23 November 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k)

Chair: David Murdoch

Members: Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Nikki Turner, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Caroline McElnay, s 9(2)(a), Daniel Bernal, Edwin Reynolds, Fiona Callaghan, Juliet Rumball-Smith, Niki Stefanogiannis, s 9(2)(a), [REDACTED], s 9(2)(a)

Guests: s 9(2)(a)

Apologies: Ian Town, s 9(2)(a)

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vac TAG Minutes 09
2.0	Protection Framework		Update	Caroline McElnay	Verbal
3.0	Update on Rollout		Update	Juliet Rumball-Smith	Verbal
4.0	Vaccine Certificates		Update	Juliet Rumball-Smith	Verbal
5.0	Vaccination in 5-11 year olds		Discussion	Dan Bernal s 9(2)(a)	 330 STA Request Advice COVID-1
6.0	Chronic fatigue/ME and vaccination		Discussion	Dan Bernal s 9(2)(a)	 ME CFS key summary points
7.0	Update from BMI Needle length study		Noting	<i>The researchers of the BMI needle length study have recruited 402 participants and finished the phase one (involving the ultrasound component and baseline finger prick</i>	

				<i>blood test). They have now started the second phase (second finger prick blood test). They further report that they are on the right track and are hoping to finish the phase to be the end of November.</i>	
8.0	Next Steps/Decisions Pending		-	All	Verbal
9.0	Any Other Business		-	All	Verbal
10.0	Agenda Items for Next Meeting		-	Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
49	Pfizer dosing error	Compile further evidence on the link between dosing intervals and reactogenicity.	Science and Technical Advisory	31/08 – Action raised
64	Supporting Evidence for Healthcare Worker Vaccination Order	Finalise evidence brief and share with CVIP and CV TAG	Science and Technical Advisory	19/10 – Action raised
68	Decision to Use 5–11-Year-Olds	Review Pfizer's application for 12-to-15-year-olds for evidence on dosages.	Medsafe	19/10 – Action raised
73	Immunocompromised populations and ATAGI's update guidance	Revise memo with CV TAG's feedback and share with CVIP	Science and Technical Advisory	02/11 – Action raised
74	Booster doses	Update and finalise memo, and circulate to Director-General	Science and Technical Advisory	09/11 – Action raised
75	Vaccination in 5-11-year-olds	Compile evidence on risk and benefits of vaccination in this age group	Science and Technical Advisory	09/11 – Action raised
76	Immunocompromised Populations and Updated Advice	Update and finalise memo, and share with CVIP	Science and Technical Advisory	09/11 – Action raised

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 30 November 2021

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Nikki Turner, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, s 9(2)(a), Caroline McElroy, s 9(2)(a), Daniel Bernal, Edwin Reynolds, Fiona Callaghan, s 9(2)(a), Juliet Rumball-Smith, s 9(2)(a), Niki Stefanogiannis, s 9(2)(a)

Guests: s 9(2)(a)

Apologies: David Murdoch

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vac TAG Minutes 23
2.0	Update on Rollout		Update	Chair	Verbal
3.0	Pfizer Vaccination in 5-11 year-olds		Discussion	Chair s 9(2)(a)	 330 STA Rf COVID-19 and V
4.0	Modelling data and assumptions		Update	Fiona Callaghan	Verbal
5.0	Vaccination after previous SARS-CoV-2 infection (primary and booster schedules)		Discussion	s 9(2)(a)	 358 STA Rf COVID-19 vacci
6.0	Update of fully vaccinated definition to include boosters		Discussion	s 9(2)(a)	 360 Definition Fully Vaccinated

7.0	ME/CFS and COVID-19 Vaccination		Update	Chair s 9(2)(a)	 TateMOH Evidence for consideration
8.0	Myocarditis research sub-TAG		Update	s 9(2)(a)	Verbal
9.0	Final Memo: Booster Vaccinations		Noting	Chair	 Memo - CV-TAG Booster vaccination
10.0	Final Memo: Decision to Use AZ		Noting	Chair	 Memo CV TAG recommendation
11.0	Next Steps/Decisions Pending		-	All	Verbal
12.0	Any Other Business		-	All	Verbal
13.0	Agenda Items for Next Meeting		-	Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
49	Pfizer dosing error	Compile further evidence on the link between dosing intervals and reactogenicity.	Science and Technical Advisory	31/08 – Action raised
64	Supporting Evidence for Healthcare Worker Vaccination Order	Finalise evidence brief and share with CVIP and CV TAG	Science and Technical Advisory	19/10 – Action raised
68	Decision to Use 5–11-Year-Olds	Review Pfizer's application for 12-to-15-year-olds for evidence on dosages.	Medsafe	19/10 – Action raised
77	Any Other Business	Share modelling data and assumptions with CV TAG	Science and Technical Advisory	23/11 - Action raised

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 07 December 2021

Time: 11:00am to 12:30pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Nikki Turner, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, s 9(2)(a), Caroline McElroy, s 9(2)(a), Daniel Bernal, Edwin Reynolds, Fiona Callaghan, s 9(2)(a), Juliet Rumball-Smith, s 9(2)(a), Niki Stefanogiannis, s 9(2)(a)

Guests: s 9(2)(a)

Apologies:

**** Supporting papers are provided IN-CONFIDENCE and are NOT for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome, Introductions and Accept Previous Minutes		Governance	Chair	 COVID-19 Vac TAG Minutes 30
2.0	Modelling data and assumptions		Update	Fiona Callaghan	Verbal
3.0	Vaccination after previous SARS-CoV-2 infection		Update	s 9(2)(a)	Verbal
4.0	Two doses of vaccine for under 18s		Update	s 9(2)(a)	Verbal
5.0	Pfizer Vaccination in 5-11 year-olds	60 min	Discussion	Chair	 330 STA Rf COVID-19 and V  archdiscchild-202 3040.full.pdf

					 Timeline for the 11 age group.  211130 DDL Ex A.pdf
6.0	Next Steps/Decisions Pending		-	All	Verbal
7.0	Any Other Business		-	All	Verbal
8.0	Agenda Items for Next Meeting		-	Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
49	Pfizer dosing error	Compile further evidence on the link between dosing intervals and reactogenicity.	Science and Technical Advisory	31/08 – Action raised
64	Supporting Evidence for Healthcare Worker Vaccination Order	Finalise evidence brief and share with CVIP and CV TAG	Science and Technical Advisory	19/10 – Action raised
68	Decision to Use 5–11-Year-Olds	Review Pfizer's application for 12-to-15-year-olds for evidence on dosages.	Medsafe	19/10 – Action raised
77	Any Other Business	Share modelling data and assumptions with CV TAG	Science and Technical Advisory	23/11 - Action raised
78	Any other business – issue of requiring two doses of vaccine for 12-15 year olds	Draft a memo outlining CV TAGs position on requiring two doses for under 18s	Science and Technical Advisory	30/11 – Action raised

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 14 December 2021

Time: 11:00am to 12:30pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Nikki Turner, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, s 9(2)(a), Caroline McElroy, s 9(2)(a), Daniel Bernal, Edwin Reynolds, Fiona Callaghan, s 9(2)(a), Juliet Rumball-Smith, s 9(2)(a), Niki Stefanogiannis, s 9(2)(a)

Guests: s 9(2)(a)

Apologies:

**** Supporting papers are provided IN-CONFIDENCE and are NOT for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccine TAG Minutes 07
2.0	CV TAG draft recommendations on vaccination in 5-11-year-olds	30 min	Discussion	Chair	 Memo - CV TAG Decision to use  330 STA Ref COVID-19 and V
3.0	Timing of Boosters		Discussion	Chair	 Memo - CV-TAG Booster vaccination  Appendix 2 - M Effectiveness of

4.0	Changes to exemption criteria		Discussion	s 9(2)(a)	 Memo to CV T Temporary Med
5.0	Vaccination after previous SARS-CoV-2 infection		Discussion	s 9(2)(a)	Verbal
6.0	Exemptions for ME/CFS		Discussion	Chair	Verbal
7.0	Next Steps/Decisions Pending		-	All	Verbal
8.0	Any Other Business		-	All	Verbal
9.0	Agenda Items for Next Meeting		-	Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
49	Pfizer dosing error	Compile further evidence on the link between dosing intervals and reactogenicity.	Science and Technical Advisory	31/08 – Action raised
64	Supporting Evidence for Healthcare Worker Vaccination Order	Finalise evidence brief and share with CVIP and CV TAG	Science and Technical Advisory	19/10 – Action raised
77	Any Other Business	Share modelling data and assumptions with CV TAG	Science and Technical Advisory	23/11 - Action raised

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Thursday 20 January 2022

Time: 11:00am to 12:30pm

Location: 9(2)(k)

Chair: Ian Town

Members: Danny de Lore, David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, James Ussher, Nikki Moreland, Nikki Turner, Owen Sinclair, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, s 9(2)(a), s 9(2)(a), Daniel Bernal, Edwin Reynolds, Fiona Callaghan, Juliet Rumball-Smith, s 9(2)(a), Niki Stefanogiannis, s 9(2)(a)

Guests: s 9(2)(a)

Apologies: Ian Frazer, Caroline McElnay, s 9(2)(a)

**** Supporting papers are provided IN-CONFIDENCE and are NOT for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes		Governance	Chair	 COVID-19 Vaccine TAG Minutes 14 Dec
2.0	Revisit discussions:		Discussion	Chair	Verbal
	2.1 Interval between doses for <30s <i>Discussion point: Does the interval between doses need to be reconsidered and lengthened in light of the risk of myocarditis?</i>				
	2.2 Vaccine certificates for under 18s <i>Discussion point: Is this clinically appropriate and aligned with advice for 5-11-year-olds? What steps have been taken from Policy?</i>				
	2.3 Myocarditis post-vaccine <i>Discussion point: Should individuals who had myocarditis after their first Pfizer dose be recommended an exemption or AstraZeneca?</i>				
	2.4 Previous infection				

	<p><i>Discussion point: Is there evidence that infection provides similar protection to one dose, or is a second primary dose needed?</i></p>				
	<p>2.5 Alternative schedule: Paediatric dose after adult dose</p> <p><i>Discussion point: For people who have an adverse reaction to Pfizer post-first dose (e.g. adolescents aged 12-15 or adults with unclear aetiology e.g. severe CFS/ME response), could the lower dose formulation be an option, and does off-label use cover it?</i></p>				
3.0	mRNA injections and aspiration		Discussion	Chair	 mRNA injections and aspiration email.pdf
4.0	<p>Booster interval final memo</p> <ul style="list-style-type: none"> • Policy change to 4 months • Updates to guidance for pregnancy and immunocompromised (now also 4 months) 		Noting	Chair	 Memo - CV-TAG - Booster vaccinations
5.0	Myocarditis Research Project Update		Noting	s 9(2)(a)	 Myocarditis - Long Term Health Outcom
6.0	Updated Exemptions		Noting	Chair	 vaccine-temporary-edical-exemption-cl
7.0	Update on Mandated Boosters		Noting	Chair s 9(2)(a)	Omicron: Government's plan to minimise risk  Omicron_ Government's pl
8.0	Decision to Use for 5–11-Year-Olds final memo		Noting	Chair	 Memo - CV TAG - Decision to use vacc
9.0	Rollout data on myocarditis in 5–11-year-olds		Noting	Chair	 mm705152a1-H.pd  bmj-2021-068665.fu l.pdf
10.0	CV TAG work for 2022 – TBC		Noting	Chair	

	<ul style="list-style-type: none"> • Heterologous schedules for boosting • 4th boosters (for immunocompromised/ all) • Definition of fully vaccinated (and boosters) • Second dose for 5–11-year-olds • Boosters for 12-15-year-olds • Roles of Janssen and AstraZeneca in the rollout • Novavax decision to use • Moderna decision to use • Vaccinating 2–5-year-olds 				
11.0	Next Steps/Decisions Pending	-	All	Verbal	
12.0	Any Other Business	-	All	Verbal	
13.0	Agenda Items for Next Meeting	-	Chair	Verbal	

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
64	Supporting Evidence for Healthcare Worker Vaccination Order	Finalise evidence brief and share with CVIP and CV TAG	Science and Technical Advisory	19/10 – Action raised

Closed Actions:

#	Agenda item	Actions	Action Owner	Updates
49	Pfizer dosing error	Compile further evidence on the link between dosing intervals and reactogenicity.	Science and Technical Advisory	31/08 – Action raised 21/12 - Work completed. Action closed

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 25 January 2022

Time: 11:00am to 12:00pm

Location: 9(2)(k)

Chair: Ian Town

Members: Danny de Lore, David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Nikki Turner, Owen Sinclair, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, s 9(2)(a), Caroline McElroy, Daniel Bernal, Edwin Reynolds, Fiona Callaghan, s 9(2)(a), Juliet Rumball-Smith, s 9(2)(a), Niki Stefanogiannis, s 9(2)(a), s 9(2)(a), Liam McConnell

Guests: s 9(2)(a)

Apologies:

**** Supporting papers are provided IN-CONFIDENCE and are NOT for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes	-	Governance	Chair	 COVID-19 Vaccine TAG Minutes 2021
2.0	Interval for boosters	10m	Discussion	Chair	Verbal
3.0	Heterologous Schedules for Booster Doses	10m	Discussion	Chair	 #395_Heterologous Booster Vaccines
4.0	Booster doses for pregnant people at 4 months	10m	Discussion	Chair Juliet Rumball Smith	 Memo - CV TAG Booster vaccines
5.0	4th Dose (first booster) for severely immunocompromised people	10m	Discussion	Chair Juliet Rumball Smith	
6.0	4th Dose (second booster) for high-risk populations	5m	Discussion	Chair	Verbal

7.0	5–11-year-olds safety data	5m	Discussion	Chair	 mm705152a1-h  bmj-2021-06866 l.pdf
8.0	Next Steps/Decisions Pending		-	All	Verbal
9.0	Any Other Business		-	All	Verbal
10.0	Agenda Items for Next Meeting		-	Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
64	Supporting Evidence for Healthcare Worker Vaccination Order	Finalise evidence brief and share with CVIP and CV TAG	STA	19/10 – Action raised
80	Interval between doses for <30s	Memo to be drafted with brief update on advice and shared with CV TAG	STA	20/01 – Action raised
81	Vaccine certificates for under 18s Previous infection	Develop clinical guidance framework on what is considered sufficient protection for CV TAG's consideration and endorsement	CVIP Clinical	20/01 – Action raised
82	Vaccine certificates for under 18s	Develop formal policy statement that CVCs should not be used among 5-11-year-olds	STA	20/01 – Action raised
84	Previous infection	Collate advice from peak bodies on immune response and vaccine recommendations.	STA	20/01 – Action raised
85	Alternative schedule: Paediatric dose after adult dose	Protocol to be developed to ensure access to paediatric doses of the vaccine are available to those who may benefit from it.	CVIP Clinical with support from STA	20/01 – Action raised
87	mRNA Injections and Aspiration	Send updated comment for statement to include comment on blood and myocarditis	STA	20/01 – Action raised

Closed Actions:

#	Agenda item	Actions	Action Owner	Updates
83	Myocarditis post-vaccine	Collate evidence on risk of myocarditis post-vaccine with AstraZeneca and Janssen	STA	20/01 – Action raised 24/01 – In heterologous RfA. Action closed.
86	Alternative schedule: Paediatric dose after adult dose	Advice to be sought on the impact on CVCs	STA	20/01 – Action raised 21/01 – Advice from Policy requested. Action closed.
88	Booster Interval Final Memo	Develop recommendation and write memo on booster interval for pregnant and immunocompromised people	STA	20/01 – Action raised 24/01 – Draft memo shared. Action closed.
89	Updated exemptions	Update language of 2.a criteria	STA	20/01 – Action raised 21/01 – Update has been requested and is the process of being signed off by the DG.

RELEASED UNDER THE OFFICIAL INFORMATION ACT

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 01 February 2022

Time: 11:00am to 12:00pm

Location: 9(2)(k)

Chair: Ian Town

Members: Danny de Lore, David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Nikki Turner, Owen Sinclair, Peter McIntyre, Sean Hanna, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Caroline McElnay, Daniel Bernal, Edwin Reynolds, Fiona Callaghan, s 9(2)(a), Juliet Rumball-Smith, s 9(2)(a), Niki Stefanogiannis, s 9(2)(a), Matt Jones, Liam McConnell, Amy Auld

Guests: s 9(2)(a)

Apologies: s 9(2)(a), Sue Crengle

**** Supporting papers are provided IN-CONFIDENCE and are NOT for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes	-	Governance	Chair	 COVID-19 Vacc TAG Minutes 25 J
2.0	Vaccine Rollout and Supply Forecast		Update	Chair	Verbal
3.0	Proposal to allow lower dose formulation in some people with ME		Discussion	s 9(2)(a)	 Proposal to allo some people to h
4.0	Uptake of vaccines by age and ethnicity		Discussion	Chair Matt Jones	 Uptake of Vaccin by Age and Ethn
5.0	Priority groups for shortened interval among 5-11-year-olds		Discussion	Chair s 9(2)(a)	 330 STA RfA COVID-19 and Va
6.0	Novavax decision to use in primary courses		Discussion	Chair	 Novavax Vaccin Science Overview

7.0	Shortened booster interval		Discussion	Chair	 CV TAG Memo_Booster In
8.0	Next Steps/Decisions Pending		-	All	Verbal
9.0	Any Other Business		-	All	Verbal
	Agenda Items for Next Meeting		-	Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
64	Supporting Evidence for Healthcare Worker Vaccination Order	Finalise evidence brief and share with CVIP and CV TAG	STA	19/10 – Action raised
80	Interval between doses for <30s	Memo to be drafted with brief update on advice and shared with CV TAG	STA	20/01 – Action raised
81	Vaccine certificates for under 18s Previous infection	Develop clinical guidance framework on what is considered sufficient protection for CV TAG's consideration and endorsement	CVIP Clinical	20/01 – Action raised
82	Vaccine certificates for under 18s	Develop formal policy statement that CVCs should not be used among 5-11-year-olds	STA	20/01 – Action raised
84	Previous infection	Collate advice from peak bodies on immune response and vaccine recommendations.	STA	20/01 – Action raised
85	Alternative schedule: Paediatric dose after adult dose	Protocol to be developed to ensure access to paediatric doses of the vaccine are available to those who may benefit from it.	CVIP Clinical with support from STA	20/01 – Action raised
93	5–11-year-olds safety data	Draft statement on 5-11-year-olds and need for boosters	STA	25/01 – Action raised
94	5–11-year-olds safety data	Collate evidence of high-risk children who may benefit from a shortened interval	STA	25/01 – Action raised

Closed Actions:

#	Agenda item	Actions	Action Owner	Updates
---	-------------	---------	--------------	---------

87	mRNA Injections and Aspiration	Send updated comment for statement to include comment on blood and myocarditis	STA	20/01 – Action raised 31/01 – Action closed.
90	Interval for boosters	Draft memo with recommendations to shorten interval	STA	25/01 – Action raised 31/01 – Action closed.
91	Booster doses for pregnant people at 4 months 4th Dose (first booster) for severely immunocompromised people	Issue recommendations to update booster recommendations	STA	25/01 – Action raised 31/01 – Action closed.
92	5–11-year-olds safety data	Request data on age and ethnicity of current uptake.	STA	25/01 – Action raised 31/01 – Action closed.
95	Booster rollout	Request data on age and ethnicity of current uptake.	STA	25/01 – Action raised 31/01 – Action closed.
96	Booster rollout	Request data on forecasting and modelling of doses.	STA	25/01 – Action raised 31/01 – Action closed.

RELEASED UNDER THE OFFICIAL INFORMATION ACT 1982

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 08 February 2022

Time: 11:00am to 12:00pm

Location: s 9(2)(k)

Chair: Ian Town

Members: Danny de Lore, David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Owen Sinclair, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, s 9(2)(a), Caroline McElnay, Daniel Bernal, Edwin Reynolds, Fiona Callaghan, s 9(2)(a), s 9(2)(a), Juliet Rumball-Smith, s 9(2)(a), Niki Stefanogiannis, s 9(2)(a)

Guests: s 9(2)(a)

Apologies: Nikki Turner, s 9(2)(a)

**** Supporting papers are provided IN-CONFIDENCE and are NOT for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes	-	Governance	Chair	 COVID-19 Vacc TAG Minutes 01 F
2.0	Vaccine Rollout		Update	Chair	Verbal
3.0	BMI Needle Length Study	10 min	Update	s 9(2)(a)	 HTS brief preliminary report v2.pdf  Statistical analysis plan - vaccination c
4.0	Novavax Decision to Use Primary Course		Discussion	Chair	 Memo CV TAG recommendation
5.0	Booster Doses in High-risk 12-17 year-olds		Discussion	Chair	 Draft_Memo - C TAG - Boosters_1

6.0	AstraZeneca Booster Dose at 3 Months		Discussion	Chair	 Memo CV TAG , booster at 3 mon
7.0	Priority Groups for Shortened Interval Among 5-11 year-olds		Discussion	Chair	 Memo CV TAG D Interval_5 to 11 Y
8.0	VAANZ Neutralising Antibody Summary ** Confidential and NOT for further distribution **		Discussion	Chair	 VAANZ neutralis antibody summa
9.0	Next Steps/Decisions Pending		-	All	Verbal
10.0	Any Other Business		-	All	Verbal
11.0	Agenda Items for Next Meeting		-	Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
64	Supporting Evidence for Healthcare Worker Vaccination Order	Finalise evidence brief and share with CVIP and CV TAG	STA	19/10 – Action raised
80	Interval between doses for <30s	Memo to be drafted with brief update on advice and shared with CV TAG	STA	20/01 – Action raised
81	Vaccine certificates for under 18s Previous infection	Develop clinical guidance framework on what is considered sufficient protection for CV TAG's consideration and endorsement	CVIP Clinical	20/01 – Action raised
82	Vaccine certificates for under 18s	Develop formal policy statement that CVCs should not be used among 5-11-year-olds	STA	20/01 – Action raised
84	Previous infection	Collate advice from peak bodies on immune response and vaccine recommendations.	STA	20/01 – Action raised
85	Alternative schedule: Paediatric dose after adult dose	Protocol to be developed to ensure access to paediatric doses of the vaccine are available to those who may benefit from it.	CVIP Clinical with support from STA	20/01 – Action raised
98	Priority groups for shortened interval among 5-11-year-olds	Formal memo to be issued to the Director-General to outline CV TAG recommendations.	STA	1/02 – Action raised

99	Novavax decision to use in primary courses	Draft a memo outlining CV TAG recommendations	STA	1/02 – Action raised
----	--	---	-----	----------------------

RELEASED UNDER THE OFFICAL INFORMATION ACT 1982

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 01 March 2022

Time: 11:00am to 12:00pm

Location: 9(2)(k)

Chair: Ian Town

Members: Danny de Lore, David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Nikki Turner, Owen Sinclair, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, s 9(2)(a), Caroline McElnay, s 9(2)(a), Daniel Bernal, Edwin Reynolds, Fiona Callaghan, s 9(2)(a), Juliet Rumball-Smith, s 9(2)(a), Niki Stefanogiannis, s 9(2)(a)

Guests: s 9(2)(a)

Apologies:

**** Supporting papers are provided IN-CONFIDENCE and are NOT for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes	-	Governance	Chair	 COVID-19 Vacc TAG Minutes 15 f
2.0	Vaccine Rollout		Update	Chair	Verbal
3.0	Future Vaccine Portfolio		Update	s 9(2)(a)	Verbal
4.0	Novavax as a Heterologous Booster		Discussion	Chair s 9(2)(a)	 395_Heterolog Booster Vaccina
5.0	Pfizer Second Booster (Fourth dose)		Discussion	Chair s 9(2)(a)	 449_Pfizer Secc Booster (Fourth
6.0	ME/CFS Trial Proposal		Discussion	Chair Dan Bernal	 CVTAG Mem Funding of an ob  Proposal to all some people to

					 Proposal_Research component vac  A Brooks Mo Budget.xlsm
7.0	CV TAG Recommendation Memos	-	Noting	Chair	
7.1	Second dose and interval for 5-11-year-olds				 Memo - CV TAG Dose Interval_5
7.2	Use of boosters in 12-17-year-olds				 Memo - CV TAG Recommendation
8.0	Next Steps/Decisions Pending	-	All		Verbal
9.0	Any Other Business	-	All		Verbal
10.0	Agenda Items for Next Meeting	-	Chair		Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
84	Previous infection	Collate advice from peak bodies on immune response and vaccine recommendations.	STA	20/01 – Action raised
85	Alternative schedule: Paediatric dose after adult dose	Protocol to be developed to ensure access to paediatric doses of the vaccine are available to those who may benefit from it.	CVIP Clinical with support from STA	20/01 – Action raised

Closed Actions Since Last Meeting:

#	Agenda item	Actions	Action Owner	Updates
98	Priority groups for shortened interval among 5-11-year-olds	Memo to incorporate Medsafe data before finalising	STA	01/02 – Action raised 15/12 – Final memo to be circulated next agenda 28/02 – Memo in agenda. Action closed
102	Boosters in 12-17 year olds	Revise memo recommendations for next CV TAG	STA	08/02 – Action raised 15/12 – Final memo to be circulated next agenda 28/02 – Memo in agenda. Action closed

107	ME/CFS trial proposal	Memo to be drafted	STA	15/12 – Action raised 28/02 – Memo in agenda. Action closed
108	Heterologous Booster	RfA to be Drafted	STA	15/12 – Action raised 28/02 – RFA in agenda. Action closed

RELEASED UNDER THE OFFICAL INFORMATION ACT 1982

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 08 March 2022

Time: 11:00am to 12:00pm

Location: 9(2)(k)

Chair: David Murdoch

Members: Danny de Lore, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Nikki Turner, Owen Sinclair, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, s 9(2)(a), Caroline McElnay, s 9(2)(a), Daniel Bernal, Edwin Reynolds, Fiona Callaghan, s 9(2)(a), Juliet Rumball-Smith, s 9(2)(a), Niki Stefanogiannis, s 9(2)(a)

Guests: s 9(2)(a)

Apologies: Ian Town, Peter McIntyre

**** Supporting papers are provided IN-CONFIDENCE and are NOT for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes	-	Governance	Chair	 COVID-19 Vacc TAG Minutes 01
2.0	CV-ISMB Update	10 min presentation 5 min for questions	Information	s 9(2)(a)	Verbal
3.0	Vaccine Rollout	Update deferred to next meeting	Information	-	-
4.0	Coadministration of Pfizer and Flu Vaccines		Discussion	s 9(2)(a)	 460_COVID-1 Vaccine Co-adm
5.0	Myocarditis and Booster Options		Discussion	s 9(2)(a)	 STA RfA Boosters myocarditis DRA

6.0	Third Dose in Severely Immunocompromised 5-11-year-olds		Discussion	s 9(2)(a)	 463_3rd dose 5 year old severe
7.0	Pre-print on Pfizer vaccine in 5-11-year-olds		Noting	s 9(2)(a)	 Pre-print.pdf
8.0	Next Steps/Decisions Pending	-	All	Verbal	
10.0	Any Other Business	-	All	Verbal	
11.0	Agenda Items for Next Meeting	-	Chair	Verbal	

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
85	Alternative schedule: Paediatric dose after adult dose	Protocol to be developed to ensure access to paediatric doses of the vaccine are available to those who may benefit from it.	CVIP Clinical with support from STA	20/01 – Action raised
109	ME/CFS Trial Proposal	Request revised protocol	STA	01/03 – Action raised
110	Any Other Business	Check timeline on updating advice regarding vaccination after infection	STA	01/03 – Action raised

RELEASED UNDER THE OFFICIAL INFORMATION ACT 1987

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 22 March 2022

Time: 11:00am to 12:00pm

Location: 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Danny de Lore, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Nikki Turner, Owen Sinclair, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, s 9(2)(a), Caroline McElnay, s 9(2)(a), Daniel Bernal, Edwin Reynolds, s 9(2)(a), Juliet Rumball-Smith, s 9(2)(a), Niki Stefanogiannis, s 9(2)(a)

Guests: s 9(2)(a)

Apologies:

**** Supporting papers are provided IN-CONFIDENCE and are NOT for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes	-	Governance	Chair	 COVID-19 Vacc TAG Minutes 08 1
2.0	Vaccine Rollout		Information	Chair	Verbal
3.0	Ministry of Health Update on COVID-19 Response <ul style="list-style-type: none"> Antibody Testing 		Information	Chair	Verbal
4.0	Third dose for severely immunocompromised 5-11-year-olds		Discussion	s 9(2)(a)	 Memo CVTAG 3 dose_immuno_5,
5.0	Future vaccine portfolio: Use of AstraZeneca		Discussion	Chair	Verbal
6.0	Second boosters for elderly/at-risk/healthcare workers		Discussion	s 9(2)(a)	 CV TAG Mem Second boosters
7.0	Next Steps/Decisions Pending	-	-	All	Verbal
8.0	Any Other Business	-	-	All	Verbal

9.0	Agenda Items for Next Meeting	-	Chair	Verbal
-----	-------------------------------	---	-------	--------

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
85	Alternative schedule: Paediatric dose after adult dose	Protocol to be developed to ensure access to paediatric doses of the vaccine are available to those who may benefit from it.	CVIP Clinical with support from STA	20/01 – Action raised
109	ME/CFS Trial Proposal	Request revised protocol	STA	01/03 – Action raised
110	Any Other Business	Check timeline on updating advice regarding vaccination after infection	STA	01/03 – Action raised
112	Myocarditis and Booster Options	Memo to be drafted and brought to CV TAG	STA	08/03 – Action raised
113	Third Dose in Severely Immunocompromised 5-11-year-olds	Memo to be drafted and brought to CV TAG	STA	08/03 – Action raised 21/03 – Memo added to the 22/03 agenda

Closed Actions Since Last Meeting:

#	Agenda item	Actions	Action Owner	Updates
84	Previous infection	Collate advice from peak bodies on immune response and vaccine recommendations.	STA	20/01 – Action raised 01/03 – Action closed as part of item 110.
98	Priority groups for shortened interval among 5-11-year-olds	Memo to incorporate Medsafe data before finalising	STA	01/02 – Action raised 15/12 – Final memo to be circulated next agenda 28/02 – Memo in agenda. Action closed
102	Boosters in 12–17-year-olds	Revise memo recommendations for next CV TAG	STA	08/02 – Action raised 15/12 – Final memo to be circulated next agenda 28/02 – Memo in agenda. Action closed
107	ME/CFS trial proposal	Memo to be drafted	STA	15/12 – Action raised 28/02 – Memo in agenda for 01/03 meeting. Action closed
108	Heterologous Booster	RfA to be Drafted	STA	15/12 – Action raised 28/02 – RFA in agenda for 01/03 meeting. Action closed

RELEASED UNDER THE OFFICAL INFORMATION ACT 1982

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 29 March 2022

Time: 11:00am to 12:00pm

Location: s 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Danny de Lore, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Nikki Turner, Owen Sinclair, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, s 9(2)(a), Caroline McElnay, s 9(2)(a), Daniel Bernal, Edwin Reynolds, s 9(2)(a), Niki Stefanogiannis, s 9(2)(a)

Guests: s 9(2)(a)

Apologies: Juliet Rumball-Smith

**** Supporting papers are provided IN-CONFIDENCE and are NOT for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes	-	Governance	Chair	 COVID-19 Vacc TAG Minutes 22
2.0	Findings of the Ka Matau, Ka Ora study		Information	s 9(2)(a)	 Ka Matau Ka C Study Report_D
3.0	Future of the National Immunisation Programme		Discussion	s 9(2)(a)	Verbal
4.0	Vaccine Rollout		Information	Chair	Verbal
5.0	Further booster doses for elderly/ at risk/ healthcare		Discussion	s 9(2)(a)	 CV TAG Mem Second booster
6.0	Novavax as a Heterologous Booster		Discussion	s 9(2)(a)	 Memo CV TAG Novavax as hete
7.0	CV TAG Recommendation Memos		Noting		

7.1	Boosters after myocarditis			 CV TAG Memo Boosters after m
7.2	Vaccination after infection			 Final Memo CV Vaccination afte
7.3	Third primary dose in immunocompromised 5-11-year-olds			 Memo CVTAG T primary dose in i
8.0	Next Steps/Decisions Pending	-	All	Verbal
9.0	Any Other Business	-	All	Verbal
10.0	Agenda Items for Next Meeting	-	Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
85	ME/CFS Alternative schedule: Paediatric dose after adult dose	Protocol to be developed to ensure access to paediatric doses of the vaccine are available to those who may benefit from it.	CVIP Clinical with support from STA	20/01 – Action raised 22/03 - In discussion
109	ME/CFS Trial Proposal	Request revised protocol	STA	01/03 – Action raised 22/03 - In progress- pending feedback
114	Second Boosters for elderly/at-risk/healthcare workers	Memo to be updated with CV TAG recommendations for next meeting	STA	22/03 – Action raised

Closed Actions Since Last Meeting:

#	Agenda item	Actions	Action Owner	Updates
110	Any Other Business	Check timeline on updating advice regarding vaccination after infection	STA	01/03 – Action raised 22/03 - Advise issued. Action closed
112	Myocarditis and Booster Options	Memo to be drafted and brought to CV TAG	STA	08/03 – Action raised 22/03 – Advise Issued. Action closed.
113	Third Dose in Severely Immunocompromised 5-11-year-olds	Memo to be drafted and brought to CV TAG	STA	08/03 – Action raised 21/03 – Memo added to the 22/03 agenda 22/03 - advice issued. Action Closed.

RELEASED UNDER THE OFFICAL INFORMATION ACT 1982

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 26 April 2022

Time: 11:00am to 12:00pm

Location: 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Danny de Lore, Elizabeth Wilson, Helen Petousis-Harris, James Ussher, Nikki Moreland, Nikki Turner, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, s 9(2)(a), Daniel Bernal, Edwin Reynolds, Juliet Rumball-Smith, s 9(2)(a), s 9(2)(a)

Guests: s 9(2)(a)

Apologies: Ian Frazer, Owen Sinclair

**** Supporting papers are provided IN-CONFIDENCE and are NOT for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes	-	Governance	Chair	 COVID-19 Vacc TAG Minutes 29 I
2.0	Active Monitoring - Post Vaccine Symptom Check - Update on Results		Information	s 9(2)(a)	 Active Monitoring Post Vaccine Sym
3.0	COVID-19 Vaccine Independent Safety Monitoring Board Interim Report		Information	Chair s 9(2)(a)	 interim_report_20 CV-ISMB.pdf
4.0	Vaccine Rollout		Information	Chair	Verbal
5.0	CV TAG Recommendation Memos		Noting		
5.1	CV TAG Memo Fourth dose for at-risk groups - Second boosters				 CV TAG Mem Fourth dose for a
6.0	Next Steps/Decisions Pending	-		All	Verbal
7.0	Any Other Business	-		All	Verbal

8.0	Agenda Items for Next Meeting	-	Chair	Verbal
-----	-------------------------------	---	-------	--------

Open Actions:

None

RELEASED UNDER THE OFFICAL INFORMATION ACT 1982

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 10 May 2022

Time: 11:00am to 12:00pm

Location: 9(2)(k)

Chair: Ian Town

Members: Danny de Lore, Elizabeth Wilson, James Ussher, Nikki Moreland, Nikki Turner, Owen Sinclair, Peter McIntyre, Sean Hanna, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Daniel Bernal, Edwin Reynolds, s 9(2)(a), Juliet Rumball-Smith, s 9(2)(a), s 9(2)(a), s 9(2)(a)

Guests: s 9(2)(a)

Apologies: David Murdoch, Ian Frazer, Helen Petousis-Harris, Nikki Turner, Sue Crengle

**** Supporting papers are provided IN-CONFIDENCE and are NOT for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes	-	Governance	Chair	 COVID-19 Vacc TAG Minutes 26
2.0	Vaccine Rollout		Information	Chair	Verbal
3.0	Aging-in the 3rd Primary Dose		Noting	Juliet Rumball-Smith	 Aging-in the 3 Primary Dose Em
4.0	CV-ISMB Interim Report: Response to questions raised last meeting.		Noting	Chair	 CV-ISMB Inter Report Email.p
5.0	Definitions of Fully Vaccinated		Discussion	s 9(2)(a)	 507 Draft RfA U date vaccination:
6.0	Future Vaccine Strategy		Discussion	Amy Auld	 513 Summary of Request for Future
7.0	CV TAG Recommendation Memos		Noting		

7.1	CV Memo Novavax as a Heterologous Booster			 Memo CV TAG Novavax as heter
8.0	Next Steps/Decisions Pending	-	All	Verbal
9.0	Any Other Business	-	All	Verbal
10.0	Agenda Items for Next Meeting	-	Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
115	COVID-19 Vaccine Independent Safety Monitoring Board Interim Report	STA to check with Post event team if WHO causality process is in use.	STA	26/04 – Action raised
116	Fourth dose for at-risk groups	Collate and report any New Zealand specific data on people who are fully vaccinated and boosted compared to those who are not.	STA	26/04 Action raised

RELEASED UNDER THE OFFICIAL INFORMATION ACT 1982

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 24 May 2022

Time: 11:00am to 12:00pm

Location: 9(2)(k)

Chair: Ian Town

Members: Danny de Lore, David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, James Ussher, Nikki Moreland, Nikki Turner, Owen Sinclair, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Daniel Bernal, Edwin Reynolds, s 9(2)(a), Jim Miller, Juliet Rumball-Smith, s 9(2)(a), s 9(2)(a), s 9(2)(a)

Guests: s 9(2)(a)

Apologies: Ian Frazer, s 9(2)(a)

**** Supporting papers are provided IN-CONFIDENCE and are NOT for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes	-	Governance	Chair	 COVID-19 Vacc TAG Minutes 10
2.0	Vaccine Rollout	5 min	Information	Chair	Verbal
3.0	Development of a National Immunisation Strategy	40 min	Discussion	s 9(2)(a)	 513 DRAFT Summary of Rec
4.0	Up to date Vaccination Status	10 min	Update	s 9(2)(a)	 507 RfA Up to d vaccination stat
5.0	NZ Data Detailing Second Booster Eligibility		Information	Chair s 9(2)(a)	 RT2820596 Urgent request  Second boost options_SG260

6.0	Long COVID Evidence Update	Information	Chair	 STA Update of long COVID - M
7.0	Next Steps/Decisions Pending	-	All	Verbal
8.0	Any Other Business	-	All	Verbal
9.0	Agenda Items for Next Meeting	-	Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
115	COVID-19 Vaccine Independent Safety Monitoring Board Interim Report	STA to check with Post event team if WHO causality process is in use.	STA	26/04 – Action raised
116	Fourth dose for at-risk groups	Collate and report any New Zealand specific data on people who are fully vaccinated and boosted compared to those who are not.	STA	26/04 Action raised
117	Vaccine rollout	Clarify with Public Health regarding when the Pfizer meeting is scheduled.	STA	10/05 – Action raised
118	Any other business	Bring in the researchers from Victoria University and the Ministry of Health team supporting the science base for the long COVID project.	STA	10/05 – Action raised

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 21 June 2022

Time: 11:00am to 12:00pm

Location: 9(2)(k)

Chair: Daniel Bernal (acting)

Members: Danny de Lore, Elizabeth Wilson, Helen Petousis-Harris, James Ussher, Nikki Turner, Owen Sinclair, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Edwin Reynolds, s 9(2)(a), Harriette Carr, Juliet Rumball-Smith, s 9(2)(a), s 9(2)(a), s 9(2)(a), s 9(2)(a)

Guests: s 9(2)(a)

Apologies: David Murdoch, Ian Frazer, Ian Town, Nikki Moreland, s 9(2)(a)

**** Supporting papers are provided IN-CONFIDENCE and are NOT for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes	-	Governance	Chair	 COVID-19 Vacc TAG Minutes 24
	Updates: <ul style="list-style-type: none"> - Medsafe Provisional Approvals - Novavax as a Second Booster 	5 min	Information	Chair	Verbal
2.0	Vaccine Rollout	5 min	Information	Chair	Verbal
3.0	Future Vaccination Strategy	5 min	Information	Chair	Verbal
4.0	Fourth Dose Update (Second Booster)	15 min	Discussion	Chair	 CV TAG Mem Second booste
5.0	Booster Eligibility for 12-15s	10 min	Discussion	Chair	 Memo - CV TA Recommendatio
6.0	Booster Eligibility for 5-11s	5 min	Information	STA	Verbal
7.0	Mortality and Hospitalisation Risk Data	5 min	Discussion	s 9(2)(a)	Verbal

8.0	Up to date Vaccination Status	Information	Chair	 507 RfA Up to d vaccination stat
9.0	Next Steps/Decisions Pending	-	All	Verbal
10.0	Any Other Business - Overview of upcoming changes and advice sought by Policy	-	All	Verbal
11.0	Agenda Items for Next Meeting	-	Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
119	Vaccine Rollout	Breakdown data categories into additional areas of boosters in 65 years and older, and 50 years and older in Māori and Pacific people	STA	24/05 – Action raised

RELEASED UNDER THE OFFICIAL INFORMATION ACT 1982

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 19 July 2022

Time: 11:00am to 12:00pm

Location: 9(2)(k)

Chair: Ian Town

Members: David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, Nikki Moreland, Nikki Turner, Owen Sinclair, Peter McIntyre, Sean Hanna, Sue Crengle

Ministry of Health Attendees: Andi Shirtcliffe, Edwin Reynolds, s 9(2)(a), Harriette Carr, Juliet Rumball-Smith, s 9(2)(a), s 9(2)(a), s 9(2)(a)

Guests: s 9(2)(a)

Apologies: Dan Bernal, Danny de Lore, James Ussher, s 9(2)(a), Tony Walls

**** Supporting papers are provided IN-CONFIDENCE and are NOT for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes 1.1 Clarification of Booster recommendations for pregnant people	-	Governance	Chair	 COVID-19 Vaccination Technical Advisory Group Minutes 21
2.0	Vaccine Rollout	5 min	Information	Chair	Verbal
3.0	Mortality and Hospitalisation Risk Data	10 min	Discussion	s 9(2)(a)	 HR COVID-19 Mortality Report  Appendix 2 Auckland Under-18s
4.0	Booster Uptake Data	5 min	Information	NIP Reporting	 Booster uptake by ethnicity and age  RT3557537 - Booster eligibility

5.0	Update on the Approach to Future Vaccination <ul style="list-style-type: none"> • Vaccines 2023 • Vaccines 2024 and Beyond • Project Plan for 2024 Vaccination 	25 min	Discussion	STA	Verbal
6.0	Updates on Topical Matters	15 min	Discussion	Chair	Verbal
7.0	Next Steps/Decisions Pending		-	All	Verbal
8.0	Any Other Business		-	All	Verbal
9.0	Agenda Items for Next Meeting		-	Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
120	2.0 Vaccine Rollout	STA to follow up with the National Immunisation Programme on whether data on booster eligibility adjusts for last vaccination and infection with COVID-19. If it doesn't adjust, STA to request for a breakdown of this information.	STA	21/06 – Action raised. Data presented does not adjust for prior infection, and the adjusted data has been requested from NIP.
121	2.0 Vaccine Rollout	STA to follow up with Intel on Analytics to obtain data breakdown comparing influenza to COVID-19 and the impact both have on hospitalisations	STA	21/06 – Action raised.
123	7.0 Mortality and hospitalisation risk data	Presented data to be circulated by Intel & Analytics to CVTAG	STA	21/06 – Action raised. This is being followed up with Intel & Analytics.
124	7.0 Mortality and hospitalisation risk data	STA to request Intel & analytics to breakdown presented data if feasible by: <ul style="list-style-type: none"> — Vaccination status — Variants or time — Age <60, <50 (disaggregate against all variables listed) — Infection vs. incidental — ICU admissions — Vaccine spacing — Co-morbidities (disaggregate against all variables listed) Type of co-morbidity	STA	21/06 – Action raised. This is being followed up with Intel & Analytics. May not be ready for distribution at the next CVTAG meeting.
125	7.0 Mortality and hospitalisation risk data	Follow up on Waikato Study for this to be presented at next CVTAG meeting.	Chair	21/06 – Action raised. Updated memo to be issued late July/early August.

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 16 August 2022

Time: 11:00am to 12:00pm

Location: 9(2)(k)

Chair: Ian Town

Members: Danny de Lore, David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, James Ussher, Nikki Moreland, Nikki Turner, Owen Sinclair, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Alison Cossar, Allison Bennett, Andi Shirtcliffe, Dan Bernal, Edwin Reynolds, s 9(2)(a) Harriette Carr, s 9(2)(a) Marion Leighton, Olivia Pearless, s 9(2)(a)

Guests: s 9(2)(a)

Apologies: s 9(2)(a), Ian Frazer,

**** Supporting papers are provided IN-CONFIDENCE and are NOT for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes Karakia	-	Governance	Chair s 9(2)(a)	 COVID-19 Vacc TAG Minutes 19
2.0	Vaccine Rollout	5 min	Information	Chair	Verbal
3.0	RFA for 2023 vaccines	10 min	Information	Chair	 DRAFT_Vacci options for 202
4.0	Novavax in 12–17-year-olds	5 min	Discussion	s 9(2)(a)	 DRAFT_CV_TAG mo_Novavax_12
5.0	Boosters in 5 – 11 and 12 - 15's	5 min	Discussion	s 9(2)(a)	Verbal
6.0	Vaccination in Under 5's	5 min	Discussion	s 9(2)(a)	<i>Document to follow</i>
7.0	Change in Post-vaccine Observation Time and the Detection of Anaphylaxis	10 min	Information	s 9(2)(a)	Verbal

8.0	Second Booster Eligibility in 30–49-year-olds	Information	STA	 Final_CVTAC memo_Extendin
9.0	Next Steps/Decisions Pending	-	All	Verbal
10.0	Any Other Business - AstraZeneca closing off	Information	Chair	Verbal
11.0	Agenda Items for Next Meeting	-	Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
121	Vaccine Rollout	STA to follow up with Intel on Analytics to obtain data breakdown comparing influenza to COVID-19 and the impact both have on hospitalisations	STA	21/06 – Action raised. Influenza uptake is being followed up with NIP, and influenza outcomes (cases, hospitalisations, deaths) being followed up with ESR.
126	Clarification of Booster recommendations for pregnant people	Collate data on flu vaccination uptake in over 65, Asian, and disabled people group.	STA/ Chair	19/07 – Action raised
127	Mortality and Hospitalisation Risk Data	A breakdown of the mortality and hospitalisation risk data was requested, broken down by disability, and age, with a comparison to influenza by age and ethnicity.	STA	19/07 – Action raised

Closed Actions Since Last Meeting:

#	Agenda item	Actions	Action Owner	Updates
123	Mortality and hospitalisation risk data	Presented data to be circulated by Intel & Analytics to CVTAG	STA	21/06 – Action raised. This is being followed up with Intel & Analytics. 19/07 – Action closed.
124	Mortality and hospitalisation risk data	STA to request Intel & analytics to breakdown presented data if feasible by: — Vaccination status — Variants or time — Age <60, <50 (disaggregate against all variables listed) — Infection vs. incidental	STA	21/06 – Action raised. This is being followed up with Intel & Analytics. 19/07 – Action closed. Noting that further disaggregation is underway (i.e. for disability) and Intel & Analytics is currently

		<ul style="list-style-type: none"> — ICU admissions — Vaccine spacing — Co-morbidities (disaggregate against all variables listed) <p>Type of co-morbidity</p>		finalising data for publication.
125	Mortality and hospitalisation risk data	Follow up on Waikato Study with Intel and Analytics team and for this to be presented at next CVTAG meeting.	Chair	<p>21/06 – Action raised. Updated memo to be issued late July/early August.</p> <p>19/07 – Action closed</p>
128	Update on the Approach to Future Vaccination	Circulate Pfizer data from the presentation given by Pfizer.	STA	<p>19/07 – Action raised</p> <p>05/08 – Link to Pfizer presentation slides circulated to CVTAG by email</p> <p>05/08 – Action closed</p>

RELEASED UNDER THE OFFICIAL INFORMATION ACT

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 13 September 2022

Time: 11:00am to 12:00pm

Location: 9(2)(k)

Chair: Ian Town

Members: Danny de Lore, David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Nikki Turner, Owen Sinclair, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Alison Cossar, s 9(2)(a), Dan Bernal, Edwin Reynolds, s 9(2)(a), Hannah Hoang, Harriette Carr, s 9(2)(a), Olivia Pearless, s 9(2)(a), s 9(2)(a)

Guests: s 9(2)(a)

Apologies: Allison Bennett, Andi Shirtcliffe, Marion Leighton

**** Supporting papers are provided IN-CONFIDENCE and are NOT for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes Karakia	-	Governance	Chair s 9(2)(a)	 COVID-19 Vacc TAG Minutes 16
2.0	Vaccine Rollout	5 min	Information	Chair	Verbal
3.0	Mortality Review Findings	10 min	Discussion	s 9(2)(a)	Verbal
4.0	Influenza Hospitalization Data	10 min	Discussion	s 9(2)(a)	Verbal
5.0	Update on Fourth Doses	10 min	Discussion	Chair	Verbal
6.0	Update on Strategic Vaccine Taskforce - Next Steps	5 min	Discussion	Chair	Verbal
7.0	NZPSU Data on Severity of COVID-19 Among Children	5 min	Discussion	s 9(2)(a)	Verbal
8.0	Update on Medsafe Myocarditis Study - Prescriber alert for Nuvaxovid issued by Medsafe	5 min	Discussion	s 9(2)(a)	Verbal
9.0	List of Research Projects that Received Ministry Funding		Information	Chair	Link

10.0	Novavax 12-17 years Primary Course Memo	Information	STA	 CV_TAG_memo_avax_12-17yo_F
11.0	Next Steps/Decisions Pending	-	All	Verbal
12.0	Any Other Business	Information	Chair	Verbal
13.0	Agenda Items for Next Meeting	-	Chair	Verbal

Open Actions:

#	Agenda item	Actions	Action Owner	Updates
129	RfA for 2023 vaccines	Chair to follow up with Waikato Study when available and bring back to CV TAG	STA	16/08 – Action raised.
130	Boosters in 5 – 11 and 12 - 15's	Request for COVID-19 hospitalisation and deaths by age group (5-11,12-15).	STA	16/08 – Action raised.
131	Boosters in 5 – 11 and 12 - 15's	Request to follow up with NZPSU on severe hospitalisations	STA	16/08 – Action raised.
132	Vaccination in Under 5's	Memo to be drafted based off RfA incorporating CV TAG feedback.	STA	16/08 – Action raised.

Closed Actions Since Last Meeting:

#	Agenda item	Actions	Action Owner	Updates
121	Vaccine Rollout	STA to follow up with Intel on Analytics to obtain data breakdown comparing influenza to COVID-19 and the impact both have on hospitalisations	STA	21/06 – Action raised. Influenza uptake is being followed up with NIP, and influenza outcomes (cases, hospitalisations, deaths) being followed up with ESR. 16/08 – Action Closed.
126	Clarification of Booster recommendations for pregnant people	Collate data on flu vaccination uptake in over 65, Asian, and disabled people group.	STA/ Chair	19/07 – Action raised 16/08 – Action Closed.
127	Mortality and Hospitalisation Risk Data	A breakdown of the mortality and hospitalisation risk data was requested, broken down by disability, and age, with a	STA	19/07 – Action raised 16/08 – Action Closed.

		comparison to influenza by age and ethnicity.		
--	--	---	--	--

RELEASED UNDER THE OFFICAL INFORMATION ACT 1982

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 11 October 2022

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: Danny de Lore, David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, Nikki Moreland, Nikki Turner, Owen Sinclair, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Alison Cossar, Allison Bennett, s 9(2)(a), Edwin Reynolds, s 9(2)(a), Hannah Hoang, Harriette Carr, Olivia Pearless, s 9(2)(a), Marion Leighton, Nicholas Jones; s 9(2)(a) s 9(2)(a)

Guests:

Apologies: James Ussher, Ian Frazer

**** Supporting papers are provided IN-CONFIDENCE and are NOT for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes Karakia	-	Governance	Chair s 9(2)(a)	 COVID-19 Vacc TAG Minutes 13 9
2.0	Vaccine Rollout	5 min	Information	Chair	Verbal
3.0	2nd Boosters for Maori and Pacific peoples 40-50 - RFA	20 min	Discussion	s 9(2)(a)	 DRAFT_CVTAC memo_Extending
4.0	6 months – 4-year-old vaccination	20 min	Discussion	s 9(2)(a)	 DRAFT_Memo of TAG Recommend
5.0	Waikato Study	2 min	Noting	Chair	Verbal
6.0	Next Steps/Decisions Pending	-	-	All	Verbal
7.0	Any Other Business	-	-	Chair	Verbal
8.0	Agenda Items for Next Meeting	-	-	Chair	Verbal

Closed Actions Since Last Meeting:

#	Agenda item	Actions	Action Owner	Updates
129	RFA for 2023 vaccines	Chair to follow up with Waikato Study when available and bring back to CV TAG	STA	16/08 – Action raised. 13/09 – Action closed.
130	Boosters in 5 – 11 and 12 - 15's	Request for COVID-19 hospitalisation and deaths by age group (5-11,12-15). Additional influenza data was requested for children under the age of 1 year and children aged 1-5 years, broken down by ethnicity, by month and in comparison to COVID-19 and ED presentations	STA	16/08 – Action raised. 13/09 – Action closed.
131	Boosters in 5 – 11 and 12 – 15's	Request to follow up with NZPSU on severe hospitalisations	STA	13/09 – Action closed.
133	Update on Strategic Vaccine Taskforce	Airfinity to report on future vaccine platforms for the next meeting	STA	13/09 – Action closed.
134	Novavax 12 – 17 years Primary Course Memo	STA to clarify with NIP messaging of Novavax dosing interval and emphasis of 8 weeks being the preferred interval between doses	STA	13/09 – Action closed. Raised with NIP. HAG to refine recommendations and bring to CVTAG
132	Vaccination in Under 5's	Memo to be drafted based off RfA incorporating CV TAG feedback.	STA	16/08 – Action raised. 10/10 – Action closed. On CVTAG agenda 11/10.

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 8 November 2022

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: Danny de Lore, David Murdoch, Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, James Ussher, Nikki Moreland, Nikki Turner, Owen Sinclair, Peter McIntyre, Sean Hanna, Sue Crengle, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Alison Cossar, s 9(2)(a), Edwin Reynolds, s 9(2)(a), [REDACTED], Hannah Hoang, Olivia Pearless, s 9(2)(a), [REDACTED], Marion Leighton, s 9(2)(a)

Apologies: Allison Bennett, Harriette Carr, Nicholas Jones

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes	-	Governance	Chair	 COVID-19 Vaccine TAG Minutes 11 Octo
2.0	Vaccine Rollout	5 min	Information	Chair	Verbal
3.0	BA.4/5 and Decision to Use	10min	Discussion	STA	 Memo CV TAG recommendations fo
4.0	Interval Duration For Next COVID-19 Dose/Booster	10min	Discussion	STA	Verbal
5.0	Moderna/Novavax as a Heterologous Booster	10min	Discussion	STA	Verbal
6.0	CV TAG Transition <i>An Update on Progress, Next Steps and Possible Support Needed From CV TAG Members as we Transition.</i>	5 min	Discussion	Chair	Verbal
7.0	< 5 Memo	1 min	Noting	Chair	 Memo CV TAG Recommendations fo
8.0	Māori and Pacific 40-49 2 nd Booster	1 min	Noting	Chair	 CV TAG Memo Extending Second Bo
9.0	Hospitalisation / Influenza Data Comparison	1 min	Noting	s 9(2)(a)	 COVID-19 Influenza hospitalisations by m

Document 45 10.0	Next Steps/Decisions Pending	-	All	Verbal
11.0	Any Other Business	-		
12.0	Agenda Items for Next TAG	-	Chair	Verbal

RELEASED UNDER THE OFFICAL INFORMATION ACT 1982

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Tuesday 6 December 2022

Time: 11:00am to 12:00pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: Elizabeth Wilson, Helen Petousis-Harris, Ian Frazer, Nikki Moreland, Nikki Turner, Owen Sinclair, Peter McIntyre, Sean Hanna, Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Alison Cossar, Brooke Hollingshead, Edwin Reynolds, s 9(2)(a), Kerry Sexton, Harriette Carr, Hannah Hoang, s 9(2)(a), Nicholas Jones, Olivia Pearless, s 9(2)(a), Vadim Pletzer

Apologies: Allison Bennett, s 9(2)(a), David Murdoch, Danny de Lore, James Ussher, Marion Leighton, s 9(2)(a), Sue Crengle

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes	-	Governance	Chair	 FINAL_COVID-19 Vaccine TAG Minutes
2.0	Thank You	10min	-	Diana Sarfati / Chair	
3.0	Vaccine Rollout	5 min	Information	Chair	Verbal
4.0	NZ and Australia Meeting on COVID-19 Vaccines	5 min	Information	s 9(2)(a)	Verbal
5.0	Dosage Intervals RfA	10 min	Discussion	s 9(2)(a)	 0596_Interval duration RfA_DRAFT
6.0	Expanding Eligibility of Second Boosters To: <ul style="list-style-type: none"> • 30+ • Pregnant people 	5 min	Discussion	Chair	Verbal
7.0	Boosters for 5-11	5 min	Discussion	s 9(2)(a)	Verbal
8.0	Vaccine Safety Surveillance Studies	10 min	Information	Olivia Pearless and Vadim Pletzer	 Myocarditis and Pericarditis following
9.0	Next Steps/Decisions Pending		-	All	Verbal
10.0	Any Other Business		-	Chair	Verbal
D11.0	Conclusion of CV TAG and NITAG Update		-	Chair	Verbal

AGENDA: COVID-19 Vaccine Technical Advisory Group

Date: Thursday 2 February 2023

Time: 3:00pm to 4:00pm

Location: [REDACTED] 9(2)(k)

Chair: Ian Town

Members: Danny de Lore, Elizabeth Wilson, Helen Petousis-Harris, James Ussher Nikki Moreland, Nikki Turner, Owen Sinclair, Sue Crengle Tony Walls

Ministry of Health Attendees: Andi Shirtcliffe, Alison Cossar, Brooke Hollingshead, Edwin Reynolds, [REDACTED] s 9(2)(a), Harriette Carr, Kerry Sexton, Hannah Hoang, [REDACTED] s 9(2)(a), [REDACTED] Nicholas Jones, Olivia Pearless, [REDACTED] s 9(2)(a), [REDACTED] s 9(2)(a), [REDACTED] Vadim Pletzer

Apologies: David Murdoch, Ian Frazer, Marion Leighton, Peter McIntyre, Sean Hanna

**** Supporting papers are provided in-confidence and are not for further distribution ****

#	Agenda Item	Duration	Purpose	Owner	Paper
1.0	Welcome and Accept Previous Minutes	-	Governance	Chair	 COVID-19 Vaccine TAG Minutes 6 Dec
2.0	Vaccine Rollout	5 min	Information	Chair	Verbal
3.0	BA.4/5 Bivalent Vaccine Update - When is the best time to roll out/swap over to bivalents? - Should all groups have access to bivalents? - Any further advice on co-administration with influenza vaccine?	20min	Discussion	STA [REDACTED] s 9(2)(a)	 DRAFT_CV TAG Memo_BA.4, BA.5 Biv
4.0	Vaccination Intervals and Expanding Booster Eligibility - What are the general guiding principles on interval duration between additional doses of vaccines? (Including low, medium, high-risk groups) - Should we expand eligibility of second boosters? If yes – which groups?	20min	Discussion	STA [REDACTED] s 9(2)(a)	 Memo - Intervals and boosters update from
5.0	Next Steps/Decisions Pending	-	-	All	Verbal
6.0	Any Other Business	-	-	Chair	Verbal